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Abstract
In South Africa and elsewhere, research has shown that the integration of antiretroviral therapy
(ART) and tuberculosis (TB) treatment saves lives. The randomised controlled trials (RCTs)
which provided this compelling evidence used intent-to-treat (ITT) strategy as part of their pri-
mary analysis. As much as ITT is protected against selection bias caused by both measured and
unmeasured confounders, but it is capable of drawing results towards the null and underestimate
the effectiveness of treatment if there is too much non-compliance. To adjust for non-compliance,
“as-treated”and “per-protocol”comparisons are commonly made. These contrast study partic-
ipants according to their received treatment, regardless of the treatment arm to which they
were assigned, or limit the analysis to participants who followed the protocol. Such analyses are
generally biased because the subgroups which they compare often lack comparability.
In view of the shortcomings of the “as-treated”and “per-protocol”analyses, our objective was
to account for non-compliance by using instrumental variables (IV) analysis to estimate the
effect of ART initiation during TB treatment on mortality. Furthermore, to capture the full
complexity of compliance behaviour outside the TB treatment duration, we developed a novel
IV-methodology for a time-varying measure of compliance to ART. This is an important con-
tribution to the IV literature since IV-methodology for the effect of a time-varying exposure
on a time-to-event endpoint is currently lacking. In RCTs, IV analysis enable us to make use
of the comparability offered by randomisation and thereby have the capability of adjusting for
unmeasured and measured confounders; they have the further advantage of yielding results that
are less sensitive to random measurement error in the exposure.
x
In order to carry out IV analysis, one needs to identify a variable called an instrument, which
needs to satisfy three important assumptions. To apply the IV methodology, we used data from
Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) trial which was con-
ducted by the Centre for the AIDS Programme of Research in South Africa. This trial enrolled
HIV and TB co-infected patients who were assigned to start ART either early or late during TB
treatment or after TB treatment completion. The results from IV analysis demonstrate that
survival benefit of fully integrating TB treatment and ART is even higher than what has been
reported in the ITT analysis since non-compliance has been accounted for.
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Chapter 1
Introduction
1.1 Overview
Globally, there were an estimated 1.2 million people co-infected with tuberculosis (TB) and hu-
man immunodeficiency virus (HIV) in 2014 and around 74% of these people live in sub-Saharan
Africa (World Health Organization, 2015). South Africa is one of the countries with the high-
est TB burden, and according to World Health Organization (2016b) there was an estimated
incidence of 454,000 cases of active TB in 2015. Among these incident TB cases, 57% are also
infected with HIV and 85% of those who are HIV infected are on antiretroviral therapy (ART)
(World Health Organization, 2016b). In some parts of South Africa, it was estimated that almost
70% of TB patients are co-infected with HIV (Perumal et al., 2014). In 2012, approximately 6.4
million people (12.2%) were HIV positive in South Africa, with the province of KwaZulu-Natal
having the highest HIV prevalence sitting at 16.2% (Shisana et al., 2012). South Africa has the
largest ART roll-out programme with approximately just over 3 million people on ART in 2015
(Department of Health, 2015).
Despite this biggest ART-roll out and wide availability of TB treatment, TB and HIV are re-
ported to be the leading causes of death in South Africa in age-groups 15 to 44 years (Statistics
South Africa, 2014). In South Africa, ART used to be deferred until TB treatment completion
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among patients with CD4+ cell count > 200 cells/mm3 (Department of Health, 2004). Most
low and middle-income countries were also following the same strategy. These guidelines were
not based on clinical trials evidence and therefore Abdool Karim et al. (2010) conducted the
Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT), an open label ran-
domised controlled trial (RCT) to determine the optimal time to initiate ART in patients with
HIV and TB co-infection who were receiving TB therapy. Results from the SAPiT trial showed
that the integration of TB and ART reduced mortality by 56%. The integration may be at the
same time or soon after the initiation of TB treatment. These results were adopted as part of
clinical guidelines and treatment policy for HIV and TB co-infected patients (Department of
Health, 2010, 2014, 2015, 2016; World Health Organization, 2009, 2016a).
Elsewhere, it was indeed confirmed that initiation of ART earlier or later during TB treatment
improves survival (Blanc et al., 2011) more especially among patients with low CD4+ cell count
(Abdool Karim et al., 2011; Havlir et al., 2011). Moreover, others showed that early initiation
of ART in patients with high CD4+ cell count is beneficial over starting when CD4+ cell count
reaches a certain threshold (Lundgren et al., 2015). The benefit of ART during TB treatment
has not only been shown for drug susceptible TB but also for patients with multi-drug resistant
tuberculosis (Padayatchi et al., 2014).
1.2 Research problem and objectives
The SAPiT trial and other open label RCTs provided remarkable evidence that the integration
of TB treatment and ART reduces mortality (Abdool Karim et al., 2010, 2011; Blanc et al.,
2011; Havlir et al., 2011). To preserve randomisation and obtain valid estimate, the ITT princi-
ple was used for their primary analysis. It is common knowledge that an ITT analysis provides
estimates for the effect of treatment assignment rather than the effect of actually taking treat-
ment. Furthermore, the analysis by treatment received suffer from selection bias where patients
who take or comply with the assigned treatment versus those who do not may have different
characteristics and therefore not be exchangeable.
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ITT analysis are relevant for public policy because they provide realistic information about the
effectiveness of implementing the intervention, keeping in mind that not everyone will adhere to
it. However, such results might not be generalised to the whole population as trial participants
are a selected group that met the trial’s inclusion criteria. Robins and Tsiatis (1991) argued
that once the treatment is proved to be efficacious in a trial, then the treatment uptake and
compliance in the community might be higher. Therefore, the ITT effect may not represent the
overall effect of treatment in the community.
As much as ITT is protected against selection bias caused by both measured and unmeasured
confounders, it may shrink results towards the null and underestimate the effectiveness of treat-
ment if there is too much non-compliance, especially in the active arm. This can potentially
result in a patient who would like to comply with the treatment in the future doubting its
benefit. According to Glymour (2006), if the ITT effect estimate is statistically significant, that
indicates the existence of a causal relationship between the outcome and treatment, however it
does not indicate the magnitude of the relationship.
Over and above the issue of non-compliance, there are other factors that may shrink results
towards the null. For example, in an open label trial, it is possible that participants randomized
to a control arm (which can be placebo) or treatment that is perceived to be inferior, may initi-
ate effective treatment outside the study. When that alternative treatment is as effective as the
intervention being studied (assuming everyone was adherent), then results will shrink towards
the null. Even when participants comply with the treatment strategy they were assigned to (i.e.
they are compliant), but if adherence is sub-optimal, then ITT results will be drawn towards
the null. For example, in HIV prevention research, there are therapeutic levels that drugs need
to reach in order to be protective against HIV acquisition. In these cases, participants can be
compliant by taking the treatment they were assigned to, but if they do not fully adhere to the
relevant dosing strategies and thus do not reach protective therapeutic levels, then ITT results
can also be pushed towards the null.
To adjust for non-compliance in RCTs, “as-treated”and “per-protocol”comparisons are com-
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monly made. These contrast study patients according to their received treatment, regardless of
the treatment arm to which they were assigned, or limit the analysis to patients who followed the
protocol. Such analyses are generally biased because the subgroups which they compare often
lack comparability. However, in instances where non-compliance is unassociated with any mea-
sured or unmeasured confounders or prognostic factors, the “as-treated”analysis produces valid
causal effects. In a scenario where non-compliance is associated with measured confounders, ad-
justing for them in a regression analyses will not render valid causal effects because that model
will not be adjusted for unmeasured confounders which might not be balanced between the
study groups. So far, instrumental variables is the only method that promises to adjust for both
measured and unmeasured confounders.
The “as-treated”and “per-protocol”analyses are also likely to be underpowered because they in-
volve either less people or fewer time-points than the ITT analysis. In the “per-protocol”analysis,
patients who violated important protocol procedures get excluded from the analyses and this
automatically reduces the sample size and may subsequently reduce the statistical power (the
likelihood of showing an effect if it exists). However, when the variability is lower among the
remaining patients who did not violate the protocol, there might be gains in the power largely
due to a potential increase in effect size. Moreover, in the “per-protocol”analysis, time-points
for data collected after protocol violations can be excluded resulting in fewer time-points be-
ing analysed than what was anticipated. In the “as-treated”analysis, participants are grouped
according to their compliance status and depending on the level of non-compliance, that allo-
cation can result in large imbalances between the groups. The imbalances can also arise in the
“per-protocol”analysis since the patients who followed the protocol may also fail to be compa-
rable between groups. Generally, deviations from equal allocation slightly reduces power. Also,
heterogeneity between compliers and noncompliers in outcome distributions affects power (Jo,
2002).
In the SAPiT trial, 642 patients with TB and HIV were randomised to initiate ART either early
or late during TB treatment or after the completion of TB treatment. Among the 362 patients
who were randomised to start ART either early or late during TB treatment, 22.4% did not
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initiate ART at the correct time (Abdool Karim et al., 2011). Moreover, following recommen-
dations by the data and safety monitoring committee (SMC), some patients started ART earlier
than the protocol specified time (Abdool Karim et al., 2010) and in this current project are
regarded as non-compliant. More details about the SAPiT trial are given in Section 3.1.
In view of the shortcomings of the “as-treated”and “per-protocol”analyses, the objective of this
study is to account for non-compliance in the SAPiT trial by using instrumental variables (IV)
analysis to estimate the effect of ART initiation during TB treatment (exposure) on mortality.
In the current analysis, non-compliance is defined as not starting ART at the correct time with
respect to TB treatment, regardless of whether that was enforced by clinicians or by patients
themselves. However, this definition of compliance does not take into account any temporary or
permanent discontinuation of study drugs as well as adherence. In particular, we assumed that
patients who were dispensed ART either early or late during TB treatment did not delay taking
it until TB treatment completion.
Most IV analyses concentrate on baseline exposures or treatment, but the reality is that in
RCTs and other biomedical studies, exposure to treatment changes over time. That part of
research on longitudinal exposures in IV analysis is still largely lacking. Therefore, our second
objective is to contribute to the IV literature by developing novel IV-methodology for time-
varying measure of compliance to ART and assess its effect on mortality. IV analysis enable us
to make use of the comparability offered by randomisation and thereby have the capability of
adjusting for unmeasured and measured confounders; they have the further advantage of yielding
results that are less sensitive to random measurement error in the exposure. Compared to ITT
analysis which provide estimates of assigning patients to integrated treatment strategy, IV results
produce estimates for the effect of receipt and complying to assigned treatment. As a result, IV
analysis appeal to patients and clinicians who are always interested in the benefits of receiving
treatment because they can provide an estimate of how receiving the assigned treatment affects
outcome. Furthermore, IV analysis have been proposed as a technique to control for bias when
using “as-treated”analysis.
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1.3 Outline of the thesis
The rest of the thesis is organised as follows:
Chapter 2 introduces the concept of IV analysis and discusses how the IV methods works. We
discuss different RCTs and other study designs where IV analyses were used. Most of the work
done on the IV methods relates to continuous and binary outcomes. Even though remarkable
work has been done on time-to-event outcomes, the field is still being developed. Therefore, in
this chapter we also discuss some of the IV work done on time-to-event outcomes which is the
outcome of interest in our analysis. We also give guidance on how to report results from the IV
analysis. Lastly, we discuss the limitations and disadvantages of using the IV method.
Chapter 3 introduces the dataset from the SAPiT trial which will be used for application of the
IV analysis. The trial enrolled patients who were co-infected with TB and HIV. The instru-
mental variable which is critical to this work, exposure variables (fixed and time-varying) and
measured covariates that will be used for modelling purposes in different statistical models are
explained in detail.
Chapter 4 presents background results from the SAPiT trial. Results of primary and secondary
outcomes of the SAPiT trial are published in different journals (Abdool Karim et al., 2010,
2011; Naidoo et al., 2014, 2012). However, data relating to these outcomes were censored at
18 months of follow-up. In this thesis we report complete data up to 24 months of follow-up.
Among others, we report baseline characteristics, mortality rates, longitudinal CD4+ count and
viral load trajectories stratified by randomisation arm.
Chapter 5 outlines the additive and proportional hazards models used in the ITT analysis and
their application using data from the SAPiT trial. Results from this Chapter will be compared
with results from the IV analysis in Chapters 6 and 7.
6
In Chapter 6 we introduce the concept of two-stage modelling, namely two-stage predictor sub-
stitution (2SPS) and two-stage residuals inclusion (2SRI) methods, which forms the basis of
most of our IV analysis. We performed the analyses based on additive and hazards regression
models using the fixed exposure.
IV-methodology for the effect of a time-varying exposure on a time-to-event endpoint is cur-
rently lacking. In Chapter 7 we extend the IV approach introduced in Chapter 6 and develop
novel IV-methodology for time-varying exposures. This was developed only for additive hazards
model under the 2SPS approach.
In Chapter 8, we summarised results from Chapters 5, 6 and 7 for ease of comparison.
Chapter 9 shows a simulation study that was conducted to assess the validity of the 2SPS esti-
mator developed in Chapter 7. The aim is to assess how much bias, if any, is introduced by the
violation of some of the IV assumptions.
Chapter 10 gives the summary of the thesis, concluding remarks and future work.
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Chapter 2
Review of instrumental variables
(IV) method
2.1 What is an instrumental variable or instrument?
In order to carry out IV analysis, one needs to identify a variable called an instrument which
needs to satisfy three important assumptions. Suppose Z, X, Y , C and U represent the instru-
ment, exposure, outcome, measured and unmeasured confounders respectively.
An instrument or instrumental variable is an observed variable which:
1. must be associated with the exposure or treatment strategy being studied (relevance as-
sumption): (i.e. Z 6⊥ X|C )
2. must have no direct effect on the outcome except through its association with the exposure
(exclusion restriction assumption): (i.e. Z ⊥⊥Y |(X,U,C))
3. must not share common causes with the outcome as shown in Figure 2.1 (exchangeability
assumption): (i.e. Z ⊥⊥U |C)
In randomised studies, the randomisation arm can be used as an instrument. However, finding
a suitable instrument in observational studies can be very challenging because it should mimic
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the randomisation arm of an RCT such that all measured and unmeasured confounders should
on average be equally distributed among different levels of a categorical instrument, leading to
exchangeability.
The second and third assumptions are untestable, however (2) is somehow ensured by double-
blind design and (3) by randomisation of the instrument. Even though double blinding can never
completely guarantee exclusion restriction, it makes it more plausible because participants are
not aware of the treatment arm they are assigned to and that does not enhance their expectation
of success or failure. Therefore, participants might be hesitant to access alternative treatment
outside the trial which could potentially introduce other pathways with which Z affects Y that
are not through X. However, we are not oblivious to the fact that treatments with visible side
effects can expose the treatment arm and thus undo the effects of double blinding. When these
assumptions are met, the IV analysis can allow one to draw causal conclusions about the effect
of exposure on the outcome in the presence of unmeasured confounders, provided that a mono-
tonicity assumption, or alternatively, a treatment homogeneity assumption is fulfilled.
The monotonicity assumption means that increasing the level of the instrument cannot lead to
a decrease in the exposure for some individuals and an increase for others. Glymour (2006)
provides this example to illustrate monotonicity “In an RCT, the monotonicity assumption
implies that there is nobody who would have refused the treatment if assigned to treatment but
would have (perversely) sought out the treatment if assigned to control”. On the other hand,
treatment homogeneity assumption means that the effect of exposure on the outcome should be
constant or similar across everybody, of which is biologically implausible.
In Figure 2.1, the strength of the correlation or association between X and Z determines whether
the instrument is strong or weak. When the correlation is weak the instrument is regarded as
weak and this affect assumption (1). The implications of a weak instrument, small sample size
and bias produced when IV assumptions are violated are discussed in Section 2.7. In Figure 2.1,
U and C represents all unobserved and observed confounders (of X and Y ) that affect both the
outcome and the decision to adhere to the assigned treatment.
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Z X Y
U
C
Figure 2.1: Causal diagram for an RCT with assignment Z, treatment X, outcome Y, unmeasured
confounders U and measured confounders C
The IV method was developed in econometrics (Goldberger, 1972; Johnson, 1963) and has been
increasingly used in medical and health research as well as in epidemiology (Greenland, 2000;
Hernan and Robins, 2006; Newhouse and McClellan, 1998; Stukel et al., 2007). In economics
and health studies, it has been used to estimate the causal effect of an exposure or treatment on
the outcome in the presence of unmeasured confounding. In epidemiology, the IV methodology
gained popularity with the special case of Mendelian randomisation (Didelez and Sheehan, 2007;
Gray and Wheatley, 1991; Smith and Ebrahim, 2004). Mendelian randomisation studies utilise
genetic factors or genotypes as instrument. The IV method also accounts for measurement error
in covariates (Carroll and Stefanski, 1994; Newhouse and McClellan, 1998; Sheiner and Rubin,
1995; Stefanski, 1996; Wright, 1928). Even though the IV method has capabilities of identifying
causal effects in the presence of unmeasured confounding, this comes at a cost. According to
Jackson and Swanson (2015), “the IV methods shift the problem of knowing, measuring, and
appropriately adjusting for confounders of the treatment-outcome relationship to confounders
of the instrument-outcome relationship (i.e. to satisfy the exchangeability assumption)”.
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2.2 How does instrumental variable method work?
IV analysis enable us to make use of the comparability offered by randomisation and thereby
have the capability of adjusting for unmeasured and measured confounders; they have the further
advantage of yielding results that are less sensitive to random measurement error in the exposure
(Vansteelandt et al., 2009). In this section we discuss how the IV method works in order to
estimate the causal effect of nonrandomised exposure (X) on the outcome (Y ), where X can
be influenced by both measured and unmeasured confounders as shown in Figure 2.1. Consider
using the model
Y = β0 + βxX + ε, (2.1)
where X is nonrandomised and therefore correlated with ε (noise). Thus βˆx will not have a
causal interpretation. To find the causal estimate, one can use the comparability offered by
the instrumental variable (Z). Here, Z and ε are uncorrelated since we are assuming Z is not
affected or influenced by measured and unmeasured confounders. To further understand how Z
can assist in finding a causal estimate (βˆx), we regress X on Z such that
X = α0 + αzZ + ω. (2.2)
Then we calculate the fitted values Xˆ=E[X|Z]=X − ω, where Xˆ represents variation in X
that is independent of the unexplained variation ε given that Z is not correlated with ε. The
instrument Z, assists in filtering out or removing the part of X that is correlated with the dis-
turbances. Now Xˆ represents the values of X that are no longer correlated with both measured
and unmeasured confounders, and it can be used in Equation 2.1 to estimate the causal effect of
X on Y . This method is referred to as the two-stage least squares and its nonlinear extension
will be presented in Chapters 6 and 7 and mainly form basis of the analytical component of this
thesis.
When Z and X are both dichotomous variables, the usual IV estimand, also known as the Wald
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estimator is given by
E[Y |Z = 1]− E[Y |Z = 0]
E[X|Z = 1]− E[X|Z = 0] , (2.3)
where Z = 1 and Z = 0 represents assignment to the intervention and control arm respectively.
The numerator of this estimator is the average causal effect of Z on Y which is the ITT effect.
The denominator is the average causal effect of Z on X which is the measure of compliance with
the assigned treatment. When there is minimal non-compliance, then E[X|Z = 1] − E[X|Z =
0] = 1 resulting in the Wald estimator being identical to the ITT estimator.
2.3 Instrumental variable method in randomised controlled tri-
als
In medical research, RCTs remain the gold standard in assessing the safety and effectiveness of
new or existing treatment because they provide strong basis for causation. RCTs are the only
clinical studies that are capable of removing bias due to confounding because treatment is ran-
domly assigned (Grimes and Schulz, 2002). They provide reliable information about the efficacy
of an intervention when the randomisation process is done perfectly. Among other things, the
problem with some of the RCTs, specifically open label trials is that of non-compliance. Par-
ticularly because everyone who is involved in the trial is unblinded, therefore participants can
decide to access the study treatment elsewhere if they feel that they have been assigned to either
inferior or harmful treatment. Moreover, in case where the trial enrols sick people, the treating
clinician or nurse can switch the patient’s treatment any time based on their prognosis. All
these issues lead to non-compliance where patients eventually receive the treatment they were
not randomly assigned to. Noncompliance is not only an obstacle to fair statistical comparison
between the intervention and the control group, but also a major threat to obtaining statistical
power to detect a significant difference between intervention and control group, if it exists (Jo,
2002).
In blinded and unblinded RCTs where both the exposure and the instrument are binary, the IV
method can be used to control for confounding due to non-compliance and participants can be
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grouped into four possible compliance groups. According to Angrist et al. (1996), the groups
are: compliers, always-takers, never-takers and defiers. Let us refer to Figure 2.1 and let Z be
the randomisation arm, X the treatment received and Y the outcome of interest. We also let
Xz and Y x denote the vector of potential treatments received under randomisation assignments
Z and the vector of potential outcomes under treatment received X, respectively.
Then the four groups are given by:
a) Compliers (X1 = 1, X0 = 0), are participants who follow the treatment strategy they are
assigned to and would receive intervention only when assigned to.
b) Always-takers (X1 = 1, X0 = 1), are participants who always take the intervention even
when assigned to the control treatment.
c) Never-takers (X1 = 0, X0 = 0), are participants who would not take the intervention even
when assigned to it.
d) Defiers (X1 = 0, X0 = 1), are the participants who would take the opposite of what they
are assigned to.
Always-takers, never-takers and defiers can be further grouped into non-compliers. Compli-
ance groups can only be formed when treatment received is a dichotomous variable with the
generalisation to continuous treatment somewhat artificial. Conducting a double blinded RCT
removes the possibility of defiance because participants do not know whether they are getting
intervention or control treatment.
In RCTs, whether open label or double blinded, the randomisation arm is mostly likely to serve
as an instrument for the treatment received and this phenomenon provides causal estimates had
every patient complied (Greenland, 2000). However, one has to keep in mind that the exclusion
restriction assumption may be vulnerable especially in open label trials due to the fact that
the knowledge of the randomisation arm may raise or dampen patient’s expectations of success
or failure. In RCT context, IV analysis can provide an estimate of how those who received
treatment were affected by it, keeping in mind that the instrument has to satisfy three impor-
tant assumptions described in Section 2.1, with the addition of monotonicity and treatment
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homogeneity assumptions. It is worth mentioning that monotonicity and treatment homogene-
ity assumptions identifies the local average treatment effect (LATE) and the average treatment
effect (ATE) estimands, respectively. Under the potential outcomes framework, we formally
define the ATE and LATE estimands as E[Y 1 − Y 0] and E[Y 1 − Y 0|X1 −X0 = 1] respectively.
ATE represents to the average casual effect in the entire population or community while LATE
measures treatment effect among the subgroup of compliers.
In this thesis, we will estimate the effect of treatment among patients who received treatment
and thus our estimand of interest is known as the average treatment effect on the treated (ATET)
formally defined as E[Y 1−Y 0|X = 1]. It must be however highlighted that in RCTs, researchers
often use ITT analysis for their primary analysis and seldom study the effect of the treatment
that participants actually received. Throughout the thesis, the notation in Figure 2.1 will be
used in different statistical models. This figure shows the IV framework in an RCT context.
When the level of non-compliance is high, X may not be the same as Z and therefore studying
the causal effect of X on Y without the use of Z will produce biased estimates as participants
who chose to comply are different from non-compliers.
2.4 Some of the instruments used in healthcare research
In this section, some of the instruments that have been used in observational studies and also in
RCTs pertaining to healthcare research will be discussed. The aim is to give readers an idea of
what variables can be potentially used as instruments. As mentioned before, the most important
aspect of the IV analysis is finding a valid instrument of high quality. Fortunately, in the current
research we have a valid instrument since we are analysing data from an RCT, where randomisa-
tion arm will be used as an instrument. In practice, more especially in observational studies, the
strong IV assumptions make it difficult to find a powerful instrument that mimics randomisation.
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Sexton and Hebel (1984) designed a randomised encouragement clinical trial to study the effect
of smoking on infant’s birth weight. One group of women were assigned to an encouragement to
stop smoking and others were not encouraged. Permutt and Hebel (1989) re-analysed that data
using the IV method as opposed to ITT and the instrumental variable was the randomisation
procedure. The treatment received was the number of cigarettes smoked per day. Since ran-
domisation took place, it was assumed that the intervention has no direct effect on birth weight
other than through the number of cigarettes smoked per day.
McClellan et al. (1994) studied the effect of more intensive treatments on mortality in elderly
patients with acute myocardial infarction (AMI). They used distance to alternative types of
hospitals as an instrument because differential distances roughly randomise patients to different
likelihoods of receiving intensive treatments. The assumption was that distance to hospital is
associated with receiving care as AMI patients should be taken to the nearest hospital due to
the seriousness of their critical condition. Patients’ differential distances to alternative types of
hospitals seemed like a strong independent predictor of how an AMI patient will be treated and
appears to be uncorrelated with their health status, thus satisfying the IV assumptions.
Angrist et al. (1996) evaluated the effect of serving in the military on health outcomes. In their
study, random assignment was done through draft lottery. Those with low lottery numbers were
assigned to serve in military. Whereas, those with high lottery numbers did not have to serve in
the military. The instrument was randomised. The authors thought it was reasonable to assume
that the draft lottery numbers have no direct effect on health outcome except through veteran
status.
Korn and Baumrind (1998) utilized the treating clinician as an instrument because each clini-
cian had preference for the choice of treatment that was given to patients. Such instruments are
called preference-based instruments. However, in this particular study, authors were sceptical
of using the IV approach because some of the assumptions in their analysis were not satisfied.
The proposed instrument was later used by Brookhart et al. (2006), to estimate the effect of
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COX-2 inhibitors on gastrointestinal toxicity, where they used a time-varying estimate of a
physician’s relative preference for a COX-2 inhibitor relative to a non-selective non-steroidal
anti-inflammatory drugs (NSAIDs) on the effect of gastrointestinal complications. If the last
prescription written by patient’s physician was a COX-2 inhibitor then the clinician is classified
as a “COX-2 prescriber”, otherwise classified as “non-selective NSAID prescriber”.
Austin et al. (2016) used an IV method to determine whether racial residential segregation lead
to lower birth weight. Railroad division index, which measures the extent to which a metropoli-
tan area was divided into subplots by railroad tracks was used an instrument. This division
made it easy to segregate blacks into racially homogeneous enclaves. This instrument has been
used before in economics research (Ananat, 2011). Austin et al. (2016) used metropolitan sta-
tistical area level segregation, quantified via the 2000 dissimilarity index as an exposure variable.
A summary of different types of instrumental variables that have been used in clinical research
can be found in the systematic review which also discusses issues in the reporting and conduct
of instrumental variables analysis (Davies et al., 2013).
2.5 Instrumental variable method in survival outcomes
In countries with high burden of HIV and TB, most RCTs that enrol HIV positive patients, with
or without TB, use time to death or time to AIDS defining illness as the main study outcome,
whereas, in HIV prevention trials time to HIV infection is usually the primary outcome. These
outcomes are preferred because they are objectively measured and they are clinically meaningful.
In this thesis, we will use the application of IV methods for time-to-event outcomes. However,
one drawback which complicates the application of IV analysis in time-to-event outcomes is the
issue of right censoring due loss to follow-up, voluntary withdrawal and many others. Right
censoring also occurs when the study ends before a participant experience an event of interest
(i.e. administrative censoring).
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The Cox proportional hazards model is widely used and most popular regression in biomedical
research. However, the IV assumptions in time-to-event outcomes can be met at the beginning
of follow-up but can possibly be violated within risk sets as censoring will force some patients
out of future risk sets. For these reasons, the Aalen’s additive hazards model (Aalen, 1989) is
a preferred regression in the context of IV analysis (Tchetgen Tchetgen et al., 2015) because
its mathematical form resembles that of linear models. Compared to the hazard ratios, another
useful property of additive hazards model is that the hazard difference is a collapsible effect
measure, such that adjusting for a variable that is neither associated with the exposure nor the
outcome will not change the magnitude of the hazard difference.
Compared to the two-stage least squares method, here the second stage regression is carried out
using additive hazards regression. IV methods are well developed for continuous (Wooldridge,
2002; Wright, 1928) and to some extent binary outcomes (Robins and Rotnitzky, 2004; Vanstee-
landt et al., 2011). Robins and Tsiatis (1991) were the first to introduce IV analysis in the
context of time-to-event outcomes. They developed G-estimation methods under a class of
structural accelerated failure time models. However, application of these methods in applied
research have been relatively low because of their complexity and often poor performance in the
presence of censoring.
Even though the field is still being developed, a lot of researchers have produced interesting
work, for example (Bijwaard and Ridder, 2005; Carslake et al., 2013; Gore et al., 2010; Hadley
et al., 2010; Li et al., 2015; Martinussen et al., 2017a,b; Stukel et al., 2007; Tan et al., 2012;
Tchetgen Tchetgen et al., 2015). In Section 2.1, we discussed three important assumptions that
the instrumental variable needs to satisfy to produce valid estimates. When the analysis involves
time-to-event outcomes, a fourth assumption needs to be added where it is assumed that censor-
ing is independent of failure processes (i.e. censoring is non-informative). Informative censoring
occurs when drop-out (censored) subjects are either more or less likely to experience the event
of interest than remaining individuals in the future (Collett, 1994). In simple terms, informative
censoring takes place when the reasons for censoring are related to the outcome of the study. In
this IV analysis, we further assume that censoring is independent of failure processes given the
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instrument, exposure and measured confounders.
Next, we highlight some of the work that has been done to estimate the causal effect of treatment
on time-to-event outcome. As mentioned already, Robins and Tsiatis (1991) were the first to in-
troduce IV methodology in time-to-event outcomes. They developed rank-preserving structural
failure time models (RPSFTM) to estimate the effect of treatment on survival outcome using
the G-estimation method. Robins and Tsiatis (1991) regarded RPSFTM as the strong version
of accelerate failure time models. The limitation about their method was that there should be
no censoring prior to the end of follow-up and no other missing data. This is an impossible
requirement when dealing with longitudinal data.
Stukel et al. (2007) used IV analysis to determine the causal effect of invasive cardiac treat-
ment on long-term mortality. They used regional cardiac catheterization rate as an instrument
because prognostic factors related to mortality were similar across regions that have different
cardiac catheterization rates. Mortality was considered as a binary variable and multiple linear
regression was used. They acknowledged that their relative mortality rates, were comparable
but not identical to those from proportional hazards models.
Similar to McClellan et al. (1994) who used the distance as an instrumental variable, Gore
et al. (2010) also used distance from the center residence zip code of each study subject to the
center of the zip code of the nearest cystectomy provider as an instrument. Their objective
was to estimate the effect of undergoing radical cystectomy for bladder cancer versus receiving
chemotherapy, radiation or surveillance on survival. The two-stage residual inclusion method
was used where proportional hazards models were used in the second stage to study the effect of
undergoing radical cystectomy for bladder cancer on survival. The two-stage residual inclusion
method (Terza et al., 2008) is discussed further in Chapter 6.
Carslake et al. (2013) used a two-sample IV method to estimate the effect of father’s height
on mortality by using the son’s height as an instrument. This two-sample method was initially
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developed by Angrist and Krueger (1992). This approach makes maximum use of the data
available on fathers mortality (even when the fathers height is not available, but his son is).
Proportional hazards models were used in the second stage model to estimate father’s all-cause
and cause-specific mortality.
Tan et al. (2012) used differential distance to a partial nephrectomy provider as an instrumen-
tal variable to determine long-term survival among patients treated with partial versus radical
nephrectomy. They calculated distance from the patients’ residence to the nearest provider
performing at least one partial nephrectomy in the year of treatment minus the distance from
the patients’ residence to the nearest surgeon performing any kidney cancer surgery. Using a
two-stage residual inclusion approach, they calculated hazard ratios using the Weibull distri-
bution to estimate the effect of treatment on survival. Models were adjusted for patient-level
covariates, surgical approach, and post-operative complications.
Hadley et al. (2010) used IV methods to estimate the causal effect of radical prostatectomy
versus conservative management on both prostate cancer-specific and all-cause mortality among
patients with early-stage prostate cancer. They selected the lagged (i.e., previous years) local
area treatment pattern for conservative management as the primary instrumental variable, be-
cause it varied substantially across geographic areas. It satisfied the key plausibility criterion
of being independent of a current patients’ health and other characteristics because it reflects
provider treatment decisions from a previous time period (i.e., the year before the patient was
diagnosed). Proportional hazards models with two-stage residual inclusion method was used.
Tchetgen Tchetgen et al. (2015) developed an IV approach for time-to-event outcomes under
the additive hazards model where two-stage regression was used for continuous exposure or en-
dogenous variables; that is, variables that share common causes with the outcomes as shown in
Figure 2.1. They also developed a control-function approach for binary exposure. The control-
function approach can also be seen as an extension of the two-stage residual inclusion approach
of Terza et al. (2008). The control-function approach works like the two-stage least squares
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method, however in the second stage of the control-function method, the outcome is regressed
on the treatment and the residuals of the first stage regression. With this work, they confirmed
the validity of the two-stage modelling under additive hazard models.
We concur with MacKenzie et al. (2014) in saying that a lot of statistical analysis in medical
research uses proportional hazards models but most IV approaches are not designed for this
regression technique. Therefore, MacKenzie et al. (2014) proposed a causal estimator within the
proportional hazards model framework. They assumed that any omitted confounders have an
additive rather than multiplicative effect on the baseline hazard. Simulation was used to justify
the use of this estimator under the proportional hazards models. However, Tchetgen Tchetgen
et al. (2015) have reservations about the validity of their estimator.
Li et al. (2015) developed a closed-form, two-stage estimator under the additive hazards models.
Compared to Tchetgen Tchetgen et al. (2015), their estimator is restrictive and only suitable for
both continuous and discrete exposures, but binary endogenous variables were not considered.
Recently, Martinussen et al. (2017b) developed IV estimator under semiparametric structural
cumulative survival models. Their models are closely related to but less restrictive than those
of Tchetgen Tchetgen et al. (2015). They can handle arbitrary exposures and instrumental
variables, and can accommodate adjustment for baseline covariates. Their approach does not
require modelling the exposure distribution nor the association between covariates and outcome,
and it deals with administrative censoring and certain forms of dependent censoring. However, it
requires a correct model for the conditional mean of the instrumental variable, given covariates,
for consistency of the estimated causal effect.
2.6 How to report instrumental variable analysis
Davies et al. (2013), Swanson and Hernan (2013) and Baiocchi et al. (2014) provided useful
guidelines on how to report results from the IV analysis. In summary, Baiocchi et al. (2014)
gave these six sub-topics on how to report IV analysis.
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• Describe the theoretical basis for the choice of an instrument: The most convincing instru-
mental variable comes from a randomised experiment or clinical trial. One has to discuss
why the IV is expected to be associated with treatment, and whether it is independent
of unmeasured confounders, and does not have a direct effect on the outcome other than
through its effect on the treatment.
• Report the strength of an instrument by showing a partial F-statistic obtained from re-
gressing treatment received (X) on the instrument (Z). Also, the proportion of compliers
and measured covariates should be reported. Other measures such as the concordance
(C-statistic) or risk difference of exposure by level of instrument can be reported.
• Report the distribution of measured covariates across levels of the instrument and received
treatment: Ideally an instrument should be unrelated to measured covariates.
• Explore concomitant treatments: One has to check whether the instrument is associated
with concomitant medications other than those in the study. Possible violations of the
exclusion restriction can be assessed by examining whether the instrument is associated
with concomitant treatments. If the instrument is associated with concomitant treatments
resulting in the violation of exclusion restriction assumption, then the IV approach may
be biased for the effect of the exposure, especially if the concomitant treatments affect the
outcome.
• Discuss the interpretation of the treatment effect estimated by the IV method.
• Report a sensitivity analysis: When the IV assumptions do not hold, one has to report
a sensitivity analysis to show how sensitive inferences are to various violations of the IV
assumption.
Baiocchi et al. (2014) gave a stern warning that newcomers to the IV methods may think that
the validity of the IV can be easily tested by regressing the outcome on the treatment received
and the instrument, and then testing whether the coefficient of the instrument is significantly
different from zero.
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2.7 Limitations and disadvantages of instrumental variable method
According to Greenland (2000), the major limitation for the IV method is that it relies mostly
on the three assumptions as discussed in Section 2.1. Two of these three assumptions are not
verifiable and as a result cannot always be tested. Weak correlation or association between the
instrument and exposure leads to less precise or biased estimates with little power (Bound et al.,
1995). When the instrument is weak enough (i.e. partial first-stage F statistics less than 10), it
is important to consider the use of other causal inference methods. This issue is escalated when
there are more than one weak instruments because that can increase finite sample bias in an IV
estimator. The combination of weak correlation between Z and X and smaller sample size can
be a threat to the validity of the IV method (Martens et al., 2006) and can have sizeable bias.
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Chapter 3
Methods
3.1 Dataset used in the thesis
We used datasets from the Centre for the AIDS Programme of Research in South Africa
(CAPRISA) for the application of the IV method. CAPRISA conducted the Starting An-
tiretroviral Therapy at Three Points in Tuberculosis (SAPiT) study, an open-label, three armed
randomised, controlled trial between 28 June 2005 and 04 July 2010. This study was conducted
in the province of KwaZulu-Natal which had and still has the highest HIV prevalence in South
Africa; 16.2% in 2012 (Shisana et al., 2012) and 27.0% in 2017 (Human Sciences Research Coun-
cil, 2018). The trial was designed to determine the optimal time to initiate ART in patients with
HIV and TB co-infection who were receiving TB therapy (Abdool Karim et al., 2010, 2011).
Each patient was expected to be followed up for a maximum of 2 years. Prior to this study,
there was no formal guidance on the timing of ART during TB treatment in South Africa. Am-
bulatory male and female patients aged 18 years or older, were enrolled. Pulmonary TB was
confirmed by acid fast bacilli smear positivity. HIV infection was confirmed by two rapid HIV
tests. All patients with a screening CD4+ count <500 cells/mm3 were initiated on a standard
TB treatment regimen.
The study was conducted at the CAPRISA’s eThekwini Clinical Research site located adjacent
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to the largest out-patient TB facility in South Africa, the Prince Cyril Zulu Communicable
Disease Centre (PCZCDC) in the city of Durban. At the PCZCDC, TB patients were treated
with a fixed drug combination of rifampicin, isoniazid, ethambutol and pyrazinamide for 2
months (intensive phase) with subsequent fixed-drug combination of isoniazid and rifampicin for
4 months (continuation phase). Patients with re-treatment TB received a 60-day intensive phase
which included streptomycin, followed by a 100-day continuation phase (Department of Health,
2004). All patients received a standard package of care which included adherence counselling and
cotrimoxazole prophylaxis. After providing written informed consent, patients were randomly
assigned in a 1:1:1 ratio (with the use of sealed opaque envelopes) to one of the three study
groups in permuted random blocks of six and nine with no stratification. Randomisation took
place at the initiation of TB treatment. A total of 642 patients were randomised to initiate ART
in the following three different points of their TB therapy:
• In the first group, antiretroviral therapy was to be initiated within 4 weeks after the start
of TB therapy (early integrated arm).
• In the second group, antiretroviral therapy was to be initiated within 4 weeks after the
completion of the intensive phase of TB therapy (i.e. within 3 months after TB treatment
initiation) (late integrated arm).
• In the third group, antiretroviral therapy was to be initiated within 4 weeks after the
completion of TB therapy (i.e. within 6-7 months after TB treatment initiation) (sequential
arm).
Patients were initiated on a once daily antiretroviral therapy regimen that contained enteric-
coated didanosine (250mg if weight <60kg and 400mg if weight ≥ 60kg), lamivudine (300mg)
and efavirenz (600mg). Notwithstanding their study group assignment, patients could be ini-
tiated on antiretroviral therapy at any time at the discretion of the study clinicians or their
personal physician.
After a planned interim analysis, on 01 September 2008, almost two months after completion of
enrolment, the data and safety monitoring committee (SMC) made a recommendation (which
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was not pre-specified in the protocol) that all patients in the sequential arm be initiated on
ART as soon as possible but continue in follow-up until study completion. The SMC also rec-
ommended continuation of the early and late integrated arms without any alterations. The
patients in the sequential arm were contacted within a week after the SMC meeting, and almost
all those that were still retained started ART within a month. All patients had demographic, be-
havioural, physical, clinical and laboratory assessments done. Following randomisation, patients
returned monthly for a period of 24 months for pill collection, physical and clinical examination.
CD4+ cell counts, HIV-1 RNA viral load and laboratory assessments for safety were conducted
at six monthly intervals or any time if clinically indicated.
The primary outcome was all-cause mortality. Information on deaths was ascertained through
hospital chart notes, death certificates and oral reports from family or relatives. Primary cause
of death was unknown for some patients. Patients who missed four consecutive visits were con-
sidered to be loss to follow-up. In the results published previously (Abdool Karim et al., 2010,
2011; Naidoo et al., 2012), administrative censoring took place at 18 months post randomisation
but for this analysis we used data up to 24 months post randomisation.
The study was approved by the Biomedical Research Ethics Committee of the University of
KwaZulu-Natal (E101/05) and the Medicines Control Council of South Africa (20060157).
3.2 Instrument
We used randomisation arm, denoted by Z as an instrument, which was modelled categorically
(using dummy coding). We assume that patients in the three study arms are exchangeable, which
is guaranteed by randomisation. However, we acknowledge that since our instrument comes from
an open-label RCT, it might, to some extent, violate the exclusion restriction assumption.
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3.3 Fixed exposure
SAPiT trial was mainly about TB and ART integration, however the study did not have an
objective measure of compliance involving ART drug levels. The fixed value denoted by X, was
defined as the fraction of time on ART during TB treatment (i.e. months on ART/months on
TB therapy). We felt that this exposure measures non-compliance due to patients not starting
ART at the correct time with respect to the TB treatment. All patients started TB treat-
ment which is not usually a problem among co-infected patients because they know that its
duration is approximately 6 months and cure or recovery is guaranteed given high adherence.
This exposure is only defined during TB treatment period regardless of how long patients were
on TB treatment for (as some took more than the expected 6 months to complete TB treatment).
We did not define compliance as a binary variable based on whether ART was initiated at the
correct time with respect to TB treatment or not, because that would have left out patients
who did not start ART. Currently, patients who were terminated before initiating ART were
assigned an exposure of zero. The rationale for choosing this exposure is that in South Africa,
TB and HIV are the leading causes of death in adults (Statistics South Africa, 2014), and TB-
HIV co-infected patients are supposed to be co-treated by the same healthcare worker for both
diseases. In a study conducted in Durban, they found that almost 70% of TB patients were co-
infected with HIV (Perumal et al., 2014). However, in resource poor countries like South Africa,
the integration has not been fully implemented. Among other things, one constraint is the low
uptake of HIV testing among TB patients which deprives patients of the treatment integration
(World Health Organization, 2015). For these reasons, this research focuses on strengthening
the evidence of the benefit of integrated therapy on survival. The application of IV method
using this exposure is shown in Chapter 6
3.4 Time-varying exposure
Among others, the limitation of using a fixed exposure over time, is that it cannot capture
the full complexity of compliance behaviour. The occurrence of death, moreover influences the
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magnitude of the exposure, in the sense that high compliance is more easily achieved amongst
early deaths, which increases the opportunity for reverse causality. In view of this, we have
moreover developed IV-methodology for a time-varying measure of compliance X(t), which we
define as 1 at time t when the considered patient was on ART at or prior to time t, and
0 otherwise. The time-varying exposure measures how much ART patients were exposed to
during the entire study participation. Mathematical formulation and results pertaining to this
exposure are shown in Chapter 7.
3.5 Outcome
We will focus on all-cause mortality. The survival time was defined as years from randomisation
until the date of death. It was censored at the withdrawal date, last visit date for those who
were loss to follow-up (LTFU) or date of the 24-month visit for those who completed the study.
3.6 Covariates
The association between X, the fraction of time on ART during TB treatment, and all-cause
mortality is confounded because patients in poorer conditions (e.g. with lower CD4+ count)
were at higher risk of death and thus more likely to initiate ART early irrespective of the study
arm. Although the considered IV analysis do not require adjustment for measured confounders,
we considered adjustment for CD4+ cell count, gender (0=male; 1=female) and employment
status (0=unemployed; 1=employed), denoted by vector C, to improve precision.
Statistical analyses were done using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and
TIMEREG package in R version 3.2.4.
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Chapter 4
Background results
In this Chapter we provide SAPiT background results so that readers can have a better un-
derstanding of patient disposition and characteristics before we move to IV analysis. Among
the 642 patients enrolled in the SAPiT trial, 214 (33.3%) were in the early integrated arm, 215
(33.5%) in the late integrated arm and 213 (33.2%) in the sequential arm. Out of the 642, only
501 (78.0%) were initiated on ART (Figure 4.1). Patient characteristics were similar across the
three study arms (Table 4.1). Patients were followed for a median (IQR) time of 24 (16.0 - 24),
24 (10.4 - 24) and 24 (8.3 - 24) months in the early integrated, late integrated and sequential
arms respectively. They were initiated on ART at a median time of 8 (IQR: 7 to 14), 85.5 (IQR:
63.5 to 118) and 239 (IQR: 195 to 271) days post randomisation in the early integrated, late
integrated and sequential arms respectively.
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Table 4.1: Baseline characteristics of patients in the SAPiT trial
Variable Early integrated Late integrated Sequential p-valuec
(N=214) (N=215) (N=213)
Mean age (SD), years 34.3 (8.0) 34.5 (8.7) 33.9 (8.2) 0.746
Number of males, n (%) 97 (45.3) 112 (52.1) 110 (51.6) 0.296
Employed, n (%) 135 (63.1) 117 (54.4) 117 (54.9) 0.123
Past history of TB, (%) 80 (37.4) 68 (31.6) 66 (31.0) 0.307
Extra pulmonary tuberculosis, n (%)a 10 (4.7) 9 (4.2) 9 (4.3) 1.000
WHO stage 4, n (%) 14 (6.5) 11 (5.1) 13 (6.1) 0.797
Median CD4+ count (IQR), 155 (75-261) 149 (77-244) 140 (69-247) 0.605
cells/mm3
Mean log10 viral load (SD), 5.0 ( 0.9) 5.0 ( 0.9) 5.1 ( 0.7) 0.250
copies/mlb
IQR: Interquartile Range SD: Standard Deviation
a 1 patient in the late integrated arm and 3 patients in the sequential arm had missing extra pulmonary and
missing data is not included in percentage calculation
b Viral load was not available for 16 patients in each of the early integrated and late integrated arms and 12 in
the sequential arm
c p-values calculated using one-way analysis of variance or Kruskal Wallis test and Fisher’s exact test
During follow-up, a total of 69 (10.7%) patients died (early integrated arm (n=17), late in-
tegrated arm (n=17) and sequential arm (n=35)); 417 (65.0%) completed the study (early
integrated arm (n=151), late integrated arm (n=139) and sequential arm (n=127)). A total of
96 (15.0%) were loss to follow-up (early integrated arm (n=26), late integrated arm (n=36) and
sequential arm (n=34)); while 60 (9.3%) either withdrew consent or relocated to other areas
((early integrated arm (n=20), late integrated arm (n=23) and sequential arm (n=17)). In ad-
dition, a total of 16 (7.5%), 51 (23.7%) and 74 (34.7%) patients never started ART in the early,
late integrated and sequential arms respectively due to reasons such as death, loss to follow-up,
relocation and voluntarily withdrawal (Figure 4.1).
Over 984.79 person-years of follow-up, the mortality rates were 4.9 per 100 person-years (py)
(95% confidence interval (CI): 2.9, 7.9) in the early integrated arm; 5.2 per 100 py (95% CI: 3.0,
8.2) in the late integrated arm and 11.3 per 100 py (95% CI: 7.9, 15.8) in the sequential arm
(Table 4.2). Mortality rates were significantly different across the three study arms at 12, 18
and 24 months of follow-up. Even though the overall mortality rate for early integrated arm is
slightly lower than that of late integrated arm, we noted that in the first six months of follow-up,
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 16 (7.5%) Did not start ART 
   4 (1.9%) Died 
   6 (2.8%) Were lost to follow-up 
   6 (2.8%) Were withdrawn 
     -4 (1.9%) Requested withdrawal 
     -1 (0.5%) Relocated 
     -1 (0.5%) Could not attend visits 
164 started ART 
 
139 started ART 
 
Early Integrated arm  
N=214 
Late Integrated arm  
N=215 
Sequential arm 
N=213 
51 (23.7%) Did not start ART 
     9 (4.2%) Died 
    24 (11.1%) Were lost to follow-up 
      2 (0.9%) Completed study without 
       initiating ART 
    16 (7.4%) Were withdrawn 
      -6 (2.8%) Requested withdrawal 
      -6 (2.8%) Relocated 
      -4 (1.9%) Were unable to comply 
         with protocol 
74 (34.7%) Did not start ART 
    30 (14.1%) Died 
    29 (13.6%) Were lost to follow-up 
    1 (0.5%) Completed study without 
         initiating ART 
   14 (6.6%) Were withdrawn 
      -3 (1.4%) Requested withdrawal 
      -3 (1.4%) Relocated 
       -7 (3.3%) Were unable to comply 
         with protocol 
       -1 (0.5%)  Will take meds in other         
          hospital 
642 Randomized 
Screened 
N= 1331 
689 Were excluded: 
130 did not return for enrolment visit 
101 beyond enrolment window 
100 returned for enrolment when   
enrolment was not open 
91 Did not have confirmed positive 
smear for acid-fast bacilli 
55 Had CD4+ count > 500 cells/mm3 
44 Declined participation 
38 Had medical reasons 
17Planned to relocate 
17 Had practical reasons 
16 Declined ART 
13 Were receiving ARV 
12 Had no sputum test 
10 Died 
  6 Were not receiving TB treatment 
  3 pregnant or planned pregnancies 
  36 Had other reasons 
198 started ART 
47 (23.7%) Did not complete study 
    13 (6.6%) Died 
    20 (10.1%) Were lost to follow-up 
    14 (7.1%) Were withdrawn 
      -5 (2.5%) Requested withdrawal 
      -8 (4.0%) Relocated 
      -1 (0.5%) Was unable to comply 
       with protocol 
27 (16.5%) Did not complete study 
   8 (4.9%) Died 
   12 (7.3%) Were lost to follow-up 
   7 (4.3%) Were withdrawn 
     -2 (1.2%) Requested withdrawal 
     -4 (2.4%) Relocated 
     -1 (0.6%) Was unable to comply 
      with protocol 
13 (9.4%) Did not complete study 
   5 (3.6%) Died 
   5 (3.6%) Were lost to follow-up 
   3 (2.2%) Were withdrawn 
      -1(0.7%) Requested withdrawal 
      -1 (0.7%) Relocated 
     - 1 (0.7%) Was unable to comply 
       with protocol 
151 completed 137 completed 126 completed 
Figure 4.1: Screening, randomisation and follow-up of patients
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mortality rate in the early integrated arm was double that of late integrated arm. Most of the
deaths occurred in the first 12 months after randomisation in all three arms (Figure 4.2, Table
4.2). Other than the study arm, gender, employment status and baseline CD4+ count were
associated with mortality. Males, unemployed patients and obviously those with low baseline
CD4+ count had a significantly higher risk of death (Table 4.3). Other studies in our setting
have linked male gender and low CD4+ count with high mortality rates (Cornell et al., 2012;
Naidoo et al., 2017).
Table 4.3: Analysis of factors associated with mortality using multivariable proportional hazards
regression
Variable Deaths/ Mortality 95% CI aHR 95%CI p-value
person-years rate/100 p-y
Sequential 35/308.96 11.3 7.9, 15.8 ref.
Early 17/345.82 4.9 2.9, 7.9 0.51 0.28, 0.91 0.024
Late 17/330.01 5.2 3.0, 8.2 0.47 0.26, 0.83 0.010
Male 44/468.11 9.4 6.8, 12.6 ref.
Female 25/516.68 4.8 3.1, 7.1 0.42 0.25, 0.71 0.001
Unemployed 41/410.87 10.0 7.2, 13.5 ref.
Employed 28/573.91 4.9 3.2, 7.1 0.39 0.24, 0.64 <0.001
Age (years) 0.97 0.83, 1.12 0.662
CD4+ count 0.73 0.64, 0.84 <0.001
(per 50 cells/mm3 increase)
aHR: adjusted hazard ratio CI: confidence interval p-y: person-years
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Figure 4.2: Kaplan-Meier curve for survival
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Figure 4.3: Instantaneous probability of death during follow-up
Figure 4.3 shows that the risk of death per unit time for both the early and late integrated
arms was fairly constant over the duration of study follow-up. However, there was a steady
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incline in the risk of death from baseline to eight months and a sharp decline thereafter in the
sequential arm. This decline did not reach the levels seen in the early and late integrated arms.
Even though the virologic response at the end of the study was impressive for patients in the
sequential arm (Figure 4.5), their immunological response was slightly lower when compared to
patients in the early integrated arm (Figure 4.4).
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Figure 4.4: Mean CD4+ count (cells/mm3) over time
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Figure 4.5: Proportion of patients with undetectable viral load (<400 copies/ml)
Treatment-limiting toxicities, drug interactions (Lalloo, 2009), high pill burden and immune
reconstitution inflammatory syndrome (IRIS) (Breen et al., 2004; Burman et al., 2007) were
shown to be associated with TB and HIV co-treatment. Despite high rates of IRIS observed
in the SAPiT trial among patients randomised to early integrated arm (Naidoo et al., 2012),
Figures 4.2 and 4.4 paints a clear picture of survival benefits and better immunological outcomes
respectively when the treatments are integrated. ARV drug changes were uncommon and not
significantly different across the three study arms (Naidoo et al., 2014). Moreover, it has been
shown that the incidence rate of loss to follow-up was lower among TB patients initiated on
ART in the SAPiT study (Yende-Zuma and Naidoo, 2016).
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Chapter 5
Intent-to-treat analysis
5.1 Introduction
Results from the IV analysis will be compared with the results from the ITT analyses to under-
stand the extent of non-compliance in the SAPiT trial. Therefore, we started with presenting
ITT results before moving to IV analysis. These analyses were based on semiparametric additive
hazards models as well as proportional hazards models. All multivariable models were adjusted
for gender, baseline CD4+ cell count and employment status.
5.2 Model formulation
We started by fitting a nonparametric additive hazards model, where the effect of Z, gender,
baseline CD4+ cell count and employment status were allowed to change over time. This way,
the regression coefficients are allowed to depend on time. The slope the cumulative regression
function plot against time gives information on whether the particular covariate has any effect
on the hazard function and whether the effect is constant or time dependent. Positive slopes
occur during time when an increase in covariate values are associated with an increase in the
hazard function. However, negative slopes occur during the times when increasing covariate
values are associated with a decrease in the hazard function. Sometimes one can observe a slope
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closer to zero which basically shows that the covariate has no effect on the hazard. When the
follow-up time is longer, one can observe all three types of slopes within the same plot.
The nonparametric model is given by:
λ(t|Z,C) = λ0(t) + βz(t)Z + βc(t)TC, (5.1)
where λ(t|Z,C) is the hazard function conditional on Z and C, λ0(t) is the unknown baseline
hazard function, βz(t) and βc(t)
T are time-dependent coefficients for the instrumental variable
and the measured confounders respectively. Even though results from model (5.1) gives us an
important information regarding whether the covariate lose or maintain their effect over time,
but we also fitted semiparametric additive and Cox proportional hazards models shown in equa-
tions (5.2) and (5.3) respectively. We will obtain constant hazard difference and hazard ratios
respectively, from these two models. These estimates have easy public health interpretation
compared to the time-varying hazards differences.
λ(t|Z,C) = λ0(t) + βzZ + βcTC, (5.2)
λ(t|Z,C) = λ0(t) exp(βzZ + βcTC). (5.3)
In these models we assumed that the randomisation arm and the baseline variables have constant
effects. Moreover, in the Cox proportional hazards models we assume that that the ratio of the
hazards for any two participants is constant over time (i.e. they are proportional). In both
equations, βz and βc
T represents the effect of randomisation arm and baseline variables (CD4+
cell count, gender and employment status) on time to death.
5.3 Results
The cumulative regression plots in Figures 5.1 and 5.2 from the nonparametric additive hazards
model show that all variables have an effect on mortality. However, study arm and employment
status have a time-varying effect on the hazard of death where we observe strong initial effect
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that seems to disappear after 12 months after randomisation. On the other hand, CD4+ count
and gender seem to have a persistent influence.
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Figure 5.1: Cumulative regression for randomisation arm
Interestingly, all variables seem to have a stronger effect on mortality during the first 12 months.
38
0 5 10 15 20
−
0.
04
−
0.
03
−
0.
02
−
0.
01
0.
00
Months after randomisation
Cu
m
u
la
tiv
e
 c
o
e
ffi
cie
nt
s
(a) CD4+ count
0 5 10 15 20
−
0.
20
−
0.
15
−
0.
10
−
0.
05
0.
00
Months after randomisation
Cu
m
u
la
tiv
e
 c
o
e
ffi
cie
nt
s
(b) Gender
0 5 10 15 20
−
0.
20
−
0.
15
−
0.
10
−
0.
05
0.
00
Months after randomisation
Cu
m
u
la
tiv
e
 c
o
e
ffi
cie
nt
s
(c) Employment
Figure 5.2: Cumulative regression for measured confounders
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It is not surprising that the effect of the arm on the hazards of death diminishes after 12 months
as there were fewer deaths observed after that period. Of the 69 deaths observed in the trial,
81% (56/69) occurred in the first 12 months of follow-up.
Table 5.1: ITT estimates for the effect of study arm on mortality
using additive hazards models
Univariable Multivariablea
Study arm β 95% CI β 95% CI
Early integrated -0.06 -0.11, -0.02 -0.05 -0.09, -0.01
Late integrated -0.06 -0.11, -0.02 -0.06 -0.11, -0.02
Sequential 0 0
a adjusted for gender, baseline CD4+ count and employment status
Multivariable results from the ITT analysis show that patients in the early and late integrated
arms had a hazard difference of -0.05 (95% CI: -0.09 to -0.01) and -0.06 (95% CI: -0.11 to -0.02)
respectively, when compared to the sequential arm (Table 5.1). This indicates that on average,
five and six deaths were averted for each year of follow-up in each 100 patients randomised to
early and late integrated arms compared with each 100 patients in the sequential arm.
Table 5.2: ITT estimates for the effect of study arm on
mortality using proportional hazards models
Univariable Multivariablea
Study arm HR 95% CI HR 95% CI
Early integrated 0.44 0.25, 0.80 0.51 0.28, 0.92
Late integrated 0.46 0.26, 0.83 0.46 0.26, 0.83
Sequential 1.0 1.0
a adjusted for gender, baseline CD4+ count and employment status
HR: hazard ratio
ITT results based on proportional hazards models showed that the hazard of death was reduced
by 49% (hazard ratio (HR): 0.51; 95% CI: 0.28 to 0.92) in the early and 54% (HR: 0.46; 95%
CI: 0.26 to 0.83) in the late integrated arm when compared to the sequential arm (Table 5.2).
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5.4 Summary
As previously shown by Abdool Karim et al. (2010), the early and late integration of TB and
ART reduced the hazard of death. Results from additive hazards models give an indication of
absolute number of deaths averted with treatment integration, whereas, hazard ratios provide
relative hazard of death which speaks to the magnitude of the association between the study
arm and time to death.
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Chapter 6
Instrumental variables analysis using
fixed exposure
6.1 Introduction
One of the objectives of this study is to account for non-compliance by using instrumental vari-
ables analysis. In Chapter 3 we introduced variables that we are going to use in IV analysis.
Here, we introduce some of them again for ease of reference. We used randomisation arm (Z) as
an instrument and by design it is independent of measured and unmeasured confounders. The
measure of compliance (X) is defined as a fraction of time on ART during TB treatment and
referred to here as fixed exposure since it was defined cross sectionally per patient. We aim to
assess the effect of X on time to death and expect the effect size from this analysis to be higher
than that of ITT analysis.
IV methods have been shown to work well under additive hazards models because its mathe-
matical form and the interpretation of the estimates resembles that of linear models. Under the
proportional hazards models, IV methods work well when the outcome is rare over the entire
follow-up (Tchetgen Tchetgen et al., 2015), which was not well satisfied in the SAPiT trial.
Therefore, the main analysis in this thesis were based on the additive hazards model while the
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proportional hazards model was used for comparison purposes.
We will use the two-stage modelling, a concept that was introduced in Section 2.2 which will form
the basis of our IV analysis. We utilised two-stage predictor substitution (2SPS) and two-stage
residuals inclusion (2SRI) methods. 2SPS is a nonlinear extension of the linear two-stage least
squares (2SLS) (Rassen et al., 2009). 2SRI was first introduced by Hausman (1978) and later
proposed for the analysis of time-to-event endpoints by Terza et al. (2008). 2SRI has been the
method of choice in clinical research involving time-to-event outcomes (Gore et al., 2010; Hadley
et al., 2010; Tan et al., 2012). Both these approaches work by fitting a first-stage, univariable or
multivariable regression models of the association between X and Z. The second-stage models
are then used for studying the effect of X on time to death as explained in Section 2.2.
6.2 Model formulation
The first-stage multivariable linear model is
X = α0 + αzZ + α
T
c C + ε, (6.1)
where α0, αz and α
T
c are coefficients for the intercept, the instrumental variable and measured
confounders respectively. Z was modelled categorically using dummy coding. The 2SPS ap-
proach then proceeds by regressing the survival time on the fitted values Xˆ from the first-stage
regression model (6.1) and on the measured confounders (C) either using additive hazard or
proportional hazards regression models. The 2SRI approach proceeds likewise, but regressing
survival time on the residuals X − Xˆ from the first-stage regression model (6.1). Tchetgen Tch-
etgen et al. (2015) showed that under certain conditions specified next, the coefficient of Xˆ in
the resulting additive hazard model can be interpreted as the exposure effect βx in the additive
hazard model
λ(t|X,Z,U,C) = λ0(t) + βxX + βTc C + βu(t)U (6.2)
which also involves adjustment for possible unmeasured confounders U .
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Deducing from Equation 6.2, exp(−βxt) can be interpreted as the relative chance of surviving
time t with exposure 1 versus 0; note that it takes the length of the exposure period into ac-
count via the value of t. For the 2SPS approach, the condition is that the error term ε in the
exposure model (6.1) is independent of randomisation arm (given the confounders). For the
2SRI approach, a more subtle additional assumption is needed, which is satisfied when the error
term (ε) equals the unmeasured confounder (U) apart from (additive) random noise. Because
tests of the null hypothesis of no exposure effect are robust against model misspecification in
the 2SPS approach (unlike the 2SRI approach), we generally recommend the 2SPS approach
(Tchetgen Tchetgen et al., 2015; Vansteelandt et al., 2011; Wooldridge, 2002).
In the 2SPS approach, the predicted exposure is a function of the IV, and thus under the null
hypothesis of no exposure effect, one would not detect an association at the 5% significance level
more than 5% of times, regardless of whether the first stage model is correct or not (Vanstee-
landt and Didelez, 2018). Indeed, even when that model is incorrect, the predicted exposure
is still a function of the IV, and thus not associated with outcome under the null hypothesis.
This is not the case with the 2SRI method where one models the residual, and where model
misspecification may induce bias (Vansteelandt et al., 2011; Vansteelandt and Didelez, 2018).
Both 2SPS and 2SRI approaches were extended to proportional hazards models even though the
outcome is not rare. 2SPS under proportional hazards models is not consistent, however Li et al.
(2015) argued that it may provide reasonable inferences in at least some empirical applications.
Under the rare event assumption, then it follows that the coefficient of Xˆ can be interpreted as
the exposure effect βx in the proportional hazards regression model
λ(t|X,Z,U,C) = λ0(t)exp(βxX + βTc C + βuU) (6.3)
but not otherwise.
Two-stage estimation has its own disadvantages, especially outside linear models. If the first-
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stage model is wrong, the standard errors in the second stage will be incorrect leading to biased
effect size. To get the correct standard errors and confidence intervals, bootstrapping methods
can be used (Efron, 1979; Efron and Tibshirani, 1993). Alternatively, the jackknife method
introduced by Angrist et al. (1999) can also be used. We generated 1000 nonparametric boot-
strap samples with replacement to calculate the standard errors and subsequently used the
bias-corrected and accelerated (BCa) method (DiCiccio and Efron, 1996) to calculate 95% con-
fidence intervals (CIs) for βx in the second-stage of both 2SPS and 2SRI. This is due to the fact
that even when the instrument is valid, IV method produces standard errors that are higher
than non-IV estimates (Little et al., 2009).
For ease of comparison with the results from the ITT analysis, we also fitted a nonparametric
additive hazards model
λ(t|X,Z,U,C) = λ0(t) + βx(t)X + βTc (t)C + βu(t)U. (6.4)
Compared to the semiparametric additive hazards model (6.2), the nonparametric model (6.4)
allows the effect of the exposure (βx(t)) to change over time. Moreover, we fitted semiparametric
additive hazards and proportional hazards models under the “as treated”analysis given by
λ(t|X,C) = λ0(t) + βxX + βTc C (6.5)
and
λ(t|X,C) = λ0(t)exp(βxX + βTc C) (6.6)
respectively. As mentioned earlier, results from the “as treated”analyses are likely biased be-
cause they disregard the randomisation arm. Compared to the IV analyses, they do not make
use of the comparability offered by randomisation. Results from the “as treated”analyses will
be compared with the results from the ITT and IV analyses (both 2SPS and 2SRI approaches),
but they will obviously be interpreted with caution.
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6.3 Results
Even though the fixed exposure was continuous and we preferred keeping it that way, we were
able to identify compliant and non-compliant patients. Among those who started ART in all
three study arms, compliance was defined as starting ART within 4 weeks after the start of
TB therapy (early integrated arm); starting ART within 4 weeks after the completion of the
intensive phase of TB therapy (late integrated arm); starting ART within 4 weeks after the
completion of TB therapy (sequential arm). Non-compliance was defined as not starting ART
at the correct time with respect to TB treatment.
Following guidance from Baiocchi et al. (2014) on how to report IV analysis, we reported the
distribution of measured covariates for compliers and non-compliers (Table 6.1). The distribution
of measured covariates across levels of the instrument was presented in Table 4.1, where we
showed that the instrument was independent of measured confounders. The 16 patients who
never started ART in the early integrated arm had the highest median baseline CD4+ count
(Table 6.1). All 24 patients from the sequential arm who were non-compliant due to starting
ART before completing TB treatment had the lowest median baseline CD4+ count. This is not
surprising as these patients were immuno-compromised and hence the decision from clinicians
to initiate them on ART earlier than expected.
The mean exposure to ART during TB treatment was 0.78, 0.39 and 0.04 in the early integrated,
late integrated and sequential arms respectively (Figure 6.1). This means that during TB
treatment, patients in the early integrated, late integrated and sequential arm spent on average
78%, 39% and 4% of the time on both ART and TB treatment respectively. Had all patients
complied with their arm assignment and also remained in the study until TB treatment is
completed, one would expect all patients in the early integrated arm to have X ≥ 0.8. Whereas,
in the late integrated arm it would have been 0.6 ≤ X <0.8 and X= 0 in the sequential arm.
The median (IQR) duration on TB treatment was 6.7 (6.4, 8.3) months in each of the three
study arms.
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Figure 6.1: Exposure (fraction of time on ART during TB treatment) in the three randomised
arms
Non-compliance is evident in Figure 6.1, as some of the patients in the sequential arm had high
exposure because they started ART before the completion of TB therapy. Also, some patients in
the early and late integrated arms had very low exposure suggesting that they delayed starting
ART.
48
0 5 10 15 20
−
0.
25
−
0.
20
−
0.
15
−
0.
10
−
0.
05
0.
00
0.
05
Months after randomisation
Cu
m
u
la
tiv
e
 c
o
e
ffi
cie
nt
s
Figure 6.2: Cumulative regression for fixed exposure under model (6.4)
Similar to the study arm, fixed exposure had time-varying effect on the hazard of to death
(Figure 6.2). This has been attributed to fewer deaths observed after 12 months of follow-up.
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We did not present the plots for measured confounders because we are mostly interested in the
results for the exposure variable.
Table 6.2: First-stage linear regression model predicting the fixed exposure
Univariable Multivariablea
Effect Estimate Std Err. Pr> |t| Estimate Std Err. Pr> |t|
Intercept 0.04 0.02 0.015 0.06 0.03 0.019
Early integrated 0.74 0.02 <.001 0.74 0.02 <.001
Late integrated 0.35 0.02 <.001 0.35 0.02 <.001
Sequential 0 0
F-value; Partial R2 514.68; 0.62 211.66; 0.62
a adjusted for gender, baseline CD4+ count and employment status
Our instrument was strong (F-value= 514.68, R2=0.62) and also associated with the exposure
(Table 6.2). Roughly, 62% of the variation in the instrument was explained by the exposure.
Table 6.3: IV estimates for the effect of exposure on mortality using
additive hazards models
Univariable Multivariablea
Method/exposure β 95% CI β 95% CI
As-treated -0.12 -0.17, -0.08 -0.12 -0.17, -0.07
2SPS -0.08 -0.14, -0.03 -0.07 -0.12, -0.01
2SRI -0.06 -0.13, -0.01 -0.05 -0.11, 0.01
First-stage residuals -0.19 -0.35, -0.06 -0.23 -0.43, -0.09
a adjusted for gender, baseline CD4+ count and employment status
Results from 2SPS analysis in Table 6.3 showed that on average, seven deaths (hazard difference=
-0.07; 95% CI: -0.12 to -0.01) were prevented for each year of follow-up in each 100 patients with
full exposure to ART during TB treatment (as would be the case under perfect compliance in the
early integrated arm) as opposed to 100 patients with no ART exposure during TB treatment
(as would be the case under perfect compliance in the sequential arm). The 2SRI method
resulted in slightly weaker effects (hazard difference = -0.05; 95% CI: -0.11; 0.01). The strong
association found between the first-stage residuals and time to death in this analysis provides
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strong evidence of unmeasured confounding, which the IV analysis accounted for. The findings
from the “as-treated”analysis (hazard difference = -0.12; 95% CI: -0.17; -0.07), showed higher
effect but likely biased.
Table 6.4: IV estimates for the effect of exposure on mortality
using proportional hazards models
Univariable Multivariablea
Method/exposure HR 95% CI HR 95% CI
As-treated 0.15 0.07, 0.31 0.14 0.06, 0.29
2SPS 0.30 0.12, 0.70 0.35 0.14, 0.85
2SRI 0.25 0.09, 0.64 0.26 0.09, 0.70
First-stage residuals 0.24 0.08, 0.71 0.18 0.05, 0.64
a adjusted for gender, baseline CD4+ count and employment status
Results from the Cox proportional hazards models are shown in Table 6.4. The 2SPS and 2SRI
methods showed that full exposure to ART during TB treatment reduced the hazard of death
by 65% (HR: 0.35; 95% CI: 0.14 to 0.85) and 74% (HR: 0.26; 95% CI: 0.09 to 0.70) respectively.
However, according to Tchetgen Tchetgen et al. (2015), results from Cox proportional hazards
models are valid when the outcome is rare over the entire follow-up duration. This also explains
why time-varying exposure analysis was not used under proportional hazards models. Results
from the “as-treated”analysis showed a stronger reduction of 86% (HR: 0.14; 95% CI: 0.06 to
0.29) in hazard of death due to full ART exposure during TB treatment (as opposed to no
exposure).
6.4 Model-based predicted survival probabilities
We calculated model-based survival probabilities for ITT and IV analysis under the 2SPS ap-
proach of the additive and proportional hazards models. In the IV analysis, the survival proba-
bilities were estimated for three fixed exposure levels of 0 (no exposure), 0.6 (partial exposure)
and 1.0 (full exposure) (Figure 6.3). These correspond to how the survival probabilities would
have looked like in the sequential, late integrated and early integrated arms, respectively, had
there been perfect compliance.
51
0 3 6 9 12 15 18 21 24
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
Early integrated Late integrated Sequential
X=1 X=0.6 X=0
0.0
Months after randomisation
P
re
d
ic
te
d
su
rv
iv
al
pr
ob
ab
ili
ty
Figure 6.3: Predicted survival curves comparing ITT and IV estimates from additive hazards
model with fixed exposure
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Figure 6.4: Predicted survival curves comparing ITT and IV estimates from proportional hazards
model with fixed exposure
In both Figures 6.3 and 6.4 the predicted survival probabilities for X=1 are slightly higher than
that of the early integrated arm. However, survival probabilities for X=0.6 and X=0 are closer
to those for late integrated and sequential arms respectively.
6.5 Sensitivity analysis 1
We saw in Figures 5.1 and 6.2 that the effect of both exposure and randomisation arm on mortal-
ity was only stronger during the first 12 months of follow-up. The accumulation of person-years
with fewer deaths after 12 months of follow-up potentially underestimated the mortality rate.
The aim of this sensitivity analysis is to understand how the results would have looked like had
the study ran for 12 rather than 24 months. We let T ∗= min(T ,12), where T is the follow-up
time defined as the minimum of time to death and time to censoring and T ∗ is the shortened
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follow-up time. For patients who died after 12 months, we let them become censored.
Table 6.5: Sensitivity: ITT and IV estimates for the effect of study arm and exposure on
mortality using additive hazards models
Univariable Multivariablea
Method/exposure β 95% CI β 95% CI
ITT Early integrated -0.11 -0.19, -0.04 -0.11 -0.19, -0.04
Late integrated -0.12 -0.19, -0.04 -0.10 -0.17, -0.03
Sequential 0 0
As-treated X -0.20 -0.28, -0.13 -0.20 -0.28, -0.12
2SPS X -0.16 -0.27, -0.06 -0.14 -0.25, -0.05
2SRI X -0.14 -0.26, -0.04 -0.12 -0.23, -0.03
First-stage residuals -0.20 -0.43, -0.01 -0.26 -0.52, -0.06
aadjusted for gender, baseline CD4+ count and employment status
As expected, sensitivity analysis produced higher effect estimates (Table 6.5) than those from
the original analysis presented in Tables 5.1 and 6.3. On average, 11 and 10 deaths were averted
for each year of follow-up in each 100 patients randomised to early and late integrated arms
compared with each 100 patients in the sequential arm. These estimates are doubled, when
compared to the original estimates of -0.05 and -0.06. Likewise, the same trend was observed
where the hazard difference changed from -0.07 and -0.05 (Table 6.3) to -0.14 and -0.12 under
the 2SPS and 2SRI approach respectively.
6.6 Sensitivity analysis 2
Earlier on, we mentioned that the initiation of ART during TB treatment has been shown to
improve survival, especially among patients with low CD4+ cell count. This may imply that the
effect of ART initiation during TB treatment differed according to baseline CD4+ cell count.
We used baseline median CD4+ cell count of 148 cells/mm3 as a cut-off point to categorise
patients to low and high CD4+ cell count levels.
Results for patients with low CD4+ cell count expressed higher effect than for those with high
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CD4+ count. This effect is even higher than that for the combined sample (see Table 6.3).
It is not surprising that the effect of ART initiation during TB treatment had no impact on
patients with high CD4+ count because most deaths [76.8% (53/69)] occurred among patients
with CD4+ count below the median and therefore that analysis lacked statistical power.
6.7 Summary
In this Chapter we have provided IV analysis of the causal effect of exposure to ART during
TB treatment on time to death. This analysis accounted for non-compliance as a result of not
all patients sticking to randomisation and starting ART at the correct time with respect to TB
treatment. The SAPiT trial data has been analysed using ITT methods and showed that integra-
tion of ART and TB treatment saves lives (Abdool Karim et al., 2010). Our results express more
precisely how many lives could be saved under perfect compliance, of which appeals to patients
and clinicians who are interested in the benefits of initiating and adhering to received treatment.
The analyses were carried out using the semiparametric additive hazards models under 2SPS and
2SRI methods. Cox proportional hazards models were used for comparison purposes. Results
from the IV analysis, which accounted for non-compliance produces slightly larger estimates
compared to the ITT results. These results demonstrate that the survival benefit of fully inte-
grating TB treatment and ART is even higher than what has been reported in the ITT analysis
since non-compliance has been accounted for. Results from the “as-treated”analysis produced
the largest estimates and one could potentially be tempted to draw conclusions from them, but
they are likely to be biased.
Large estimates observed when follow-up was censored at 12 months are an indication that the
benefit of ART and TB integration was seen as early as 12 months while revealing the extent of
early mortality. After 12 months, only 9 deaths were observed and the study continued accu-
mulating person-years and thus reducing mortality rate across all study arms. In our settings,
it has been shown that early mortality among adult patients accessing ART programmes is
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high (Lawn et al., 2008), due to patients presenting late for care with advanced clinical diseases
(Kigozi et al., 2009; Lawn et al., 2005). Studies done elsewhere showed that late presentation to
care is still rife even when the eligibility threshold was increased or when ART was recommended
irrespective of CD4+ cell count (Darcis et al., 2018; Fomundam et al., 2017; Larsen et al., 2018;
Nyika et al., 2016).
The validity and interpretation of IV estimates is built on three key strong assumptions. There is
also a fourth and also strong assumption about treatment homogeneity. The first, that patients
on the different arms of the study are exchangeable, is guaranteed by randomisation. Secondly,
that the instrument is associated with exposure is shown in Table 6.2. The third, so-called exclu-
sion restriction, that randomised assignment may only influence all-cause-mortality by changing
ART exposure could be violated. One possible cause of violation concerns our definition of
exposure, which may not fully capture all relevant components such as adherence which could
have an effect on mortality. A second possible reason is that, in the open-label SAPiT trial,
being assigned to either of the integrated arms may have enhanced patients expectation of suc-
cess, and in contrast, assignment to the sequential arm might have reduced such an expectation.
Moreover, those randomised to integrated arms who did not start ART soon after TB treatment
initiation might have deliberately delayed ART initiation because they were still feeling well
and did not see the need to integrate TB treatment and ART. Our analysis moreover ignored
differential ART exposure outside the TB treatment window. All of this in turn violates the
exclusion restriction assumption, which underlies our analysis. The violation of this untestable
assumption can lead to biased IV estimates. Lastly, through treatment homogeneity we assume
that TB treatment and ART has the same effect for compliers and defiers.
Tchetgen Tchetgen et al. (2015) and Li et al. (2015) validated the two-stage estimation method
under the additive hazards models. In linear models, the two-stage estimation method, namely
2SLS is robust against first-stage regression model misspecification (Wooldridge, 2002). How-
ever, the 2SPS and 2SRI requires the first-stage regression to be correctly specified in order
for the IV estimates to be valid (Tchetgen Tchetgen et al., 2015). Furthermore, 2SPS requires
the error term (ε) in model (6.1) to be independent of randomisation arm given, the measured
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confounders. When it comes to Cox proportional hazards models, the 2SPS and 2SRI methods
are not guaranteed to produce valid estimates unless the incidence proportion is relatively low
during follow-up.
We acknowledge several additional limitations in our analyses. Our fixed exposure did not
differentiate between patients who were on TB treatment for six months and those who were on
TB treatment for a longer period. A patient who was on TB treatment for six months and only
took ART for three months had similar exposure level to a patient who was on TB treatment for
12 months and took ART for 6 months. The latter patient is more likely to have drug resistant
TB and thus more likely to die. Also, for patients who died soon after enrolment and those who
did not start ART, the exposure is not well defined. Moreover, this exposure can potentially
introduce reverse causality especially among those who either died or were terminated early. We
believe this somehow explains why the ITT and IV estimates under the additive hazards models
are not that dramatically different.
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Chapter 7
Instrumental variables analysis using
time-varying exposure
7.1 Introduction
IV-methodology for the effect of a time-varying exposure on a time-to-event endpoint is cur-
rently lacking, with the exception of G-estimation for structural accelerated failure time models
(Robins and Tsiatis, 1991). While G-estimation strategies have been proposed to infer the effect
of a time-varying exposure on a time-to-event endpoint in the presence of an instrumental vari-
able under an alternative class of structural accelerated failure time models (Robins and Tsiatis,
1991), application of these methods in applied research has been relatively infrequent because
of their complexity and often poor performance in the presence of censoring (Vansteelandt and
Joffe, 2014a).
In this Chapter, we developed a novel IV-methodology for time-varying exposure under additive
hazard models. Our proposal overcomes above-mentioned concerns because it is applicable in
standard software for additive hazard models, which naturally accommodates non-informative
censoring without requiring further adjustments. Over and above the lack of IV methodology for
time-varying exposure, we developed this method due to the limitations of our fixed exposure
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discussed in Chapter 6. Among others, it cannot capture the full complexity of compliance
behaviour and may, moreover, be indirectly influenced by censoring or death. The time-varying
measure of compliance (X(t)) to ART is defined as 1 at time t when the considered patient was
on ART at or prior to time t, and 0 otherwise. We will assess the effect of X(t) on time to death
using under the 2SPS approach. Our IV analysis based on this exposure will express the effect
of continuous ART use versus no ART use (regardless of TB treatment).
7.2 Model formulation
Let λ(t) be the conditional hazard at time t given X(t), Z and U , where X(t) is the exposure
at time t, Z is the instrument and U represents unmeasured confounders of the association
between the exposure (X(t)) and the time-to-event endpoint (T ). Let dN(t) be the increment
in the counting process related to the event at time t. Then λ(t) is more precisely defined as
E
{
dN(t)|T ≥ t, X¯(t), Z, U}, where X¯ is the history of exposure up to time t. Consider the
model
λ(t) = ω(t, U) + βX(t) (7.1)
and for subjects with T ≥ t, let
X(t) = E
{
X(t)|T ≥ t, Z}+ ∆(t), (7.2)
where we assume ∆(t) is independent of Z among subjects alive at time t. Therefore, the
conditional hazard at time t is given by
λ∗(t) ≡ E{dN(t)|T ≥ t, Z, U} = ω∗(t, U) + βE{X(t)|T ≥ t, Z},
where E
{
X(t)|T ≥ t, Z} ≡M(t) such that
λ∗(t) ≡ E{dN(t)|T ≥ t, Z, U} = ω∗(t, U) + βM(t),
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and
ω∗(t, U) = ω(t, U)− d
dt
logE
[
exp
{− β∆(t)|T ≥ t, Z, U}]
= ω(t, U)− d
dt
logE
[
exp
{− β∆(t)|T ≥ t, U}].
It further follows that
P (T ≥ t|Z,U) = exp
[
−
∫ t
0
{
ω∗(s, U) + βM(s)
}
ds
]
from which, by Bayes’ rule
f(Z,U |T ≥ t) = exp
[
−
∫ t
0
ω∗(s, U)ds
]
exp
[
−
∫ t
0
βM(s)ds
]f(Z)f(U)
P (T ≥ t) .
We note that M(s) is a deterministic function of time and the baseline Z and not a time-varying
covariate. Factorisation of this joint density into terms involving either Z or U demonstrate that
Z⊥⊥U |T ≥ t for all t > 0. Using this, we can now demonstrate that the following estimating
equation for β,{
M(t)−E[M(t)|T ≥ t]}R(t){dN(t)−βM(t)dt}, where M(t) ≡ E{X(t)|T ≥ t, Z} is unbiased,
where R(t) is the at risk indicator.
Indeed, its expectation equals
E
({
M(t)− E[M(t)|T ≥ t]}R(t){dN(t)− βM(t)dt})
= E
({
M(t)− E[M(t)|T ≥ t]}R(t){ω(t, U)dt+ β∆(t)dt})
Since M(t) is a function of Z only, and Z⊥⊥U |T ≥ t, we have that
E
({
M(t)− E[M(t)|T ≥ t]}R(t){ω(t, U)dt+ β∆(t)dt}) = 0.
Since ∆(t) is independent of Z among subjects alive at time t, we further have that
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E
({
M(t)− E[M(t)|T ≥ t]}R(t)β∆(t)dt) = 0.
A consistent estimator of β can thus be obtained by solving an estimating equation based on
the above estimating function such that
βˆ =
[ n∑
i=1
{
Mi(t)− E[Mi(t)|Ti ≥ t]
}
dNi(t)
][ n∑
i=1
{
Mi(t)− E[Mi(t)|Ti ≥ t]
}
Mi(t)Ri(t)
]−1
for i = 1, . . . , n individuals.
It follows from Vansteelandt et al. (2014b) that the Aalen least squares estimator under the
model
λ˜(t) = ψ0(t) + βM(t) (7.3)
solves precisely such an equation, thus confirming the validity of the 2SPS estimator.
Using the 2SPS approach, the first-stage model for X(t) is given by
X(t) = α0(t) + αz(t)Z + α
T
c (t)C + ε(t) (7.4)
defined for patients who are alive at time t, which we consider at each observed event time t.
Under the assumption that ε(t) is uncorrelated with Z, conditional on C (vector of measured
confounders) for patients who are alive at time t, then show that the 2SPS approach can be
extended to an additive hazard regression of the survival time on the fitted values Xˆ(t) from
the first-stage regression (model 7.4). In particular, we show that the resulting effect βx of Xˆ(t)
can be interpreted as the effect of X(t) in the additive hazard model
λ(t|X¯(t), Z, U,C) = λ0(t) + βxX(t) + βTc C + βu(t)U. (7.5)
However, since X(t) is a binary variable, model (7.4) is substituted by the logit model.
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7.2.1 Model formulation with time-varying unmeasured confounders
Next, we show that the proposed IV approach for time-varying exposure is valid in the presence
of time-varying unmeasured confounders. Consider, without loss of generality, a study design
which intends to collect data on an instrumental variable Z at baseline (time t = 0), on exposure
measurements X(t) taken at discrete time points t = 0, 1, ...,K and on time to death T . The
exposure measurements are only recorded up to the time of death, the time L to censoring or the
end K of the measurement period, whichever comes first. For each individual, we thus observe
the following data: Z, T ∗ ≡ min(T, L),∆ ≡ I(T ≤ L), X¯ ≡ min(T ∗,K), where X¯(t) refers to
the history of the exposure measurements X(s) at the discrete times s = 0, 1, ... up to time t.
Further, let U(t) be a vector of unmeasured variables such that for each time t = 0, 1, ...,K, the
history U¯(t) along with X¯(t− 1) is sufficient to adjust for confounding of the effect of X(t) on
T among individuals who are alive at that time (i.e., for whom T ≥ t).
Throughout, we will assume that U(t) at each time t is not influenced by the previous exposure
measurements X¯(t− 1). While this is a potentially strong assumption, it is one that is difficult
to relax in IV analysis. Indeed, without this assumption, there may be pathways from the
instrumental variable Z via X¯(t − 1) and U(t) towards the time-to-event endpoint, thereby
inducing a dependence between the instrumental variable and the unmeasured confounders,
and thus violating the instrumental variables assumptions. This assumption is therefore often
implicitly implied by common IV analysis which ignore the time-varying nature of the exposure.
More formally, we will impose the generalised IV assumption
U(btc)⊥⊥Z|T ≥ t, U¯(btc − 1), (7.6)
at each measurement time t = 0, 1, ...,K, where we define U¯(−1) ≡ ∅ and btc to be the integer
value just below (or equal to) t. It is indeed seen from the causal diagram in Figure 7.1 that
this assumption is justified when U(t) at each time t is not influenced by the previous exposure
measurements X¯(t− 1).
Let λ(t) be the conditional hazard at time t, given X¯(btc), U¯(btc) and Z. Let dN(t) be the
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Figure 7.1: Causal diagram with time-varying exposure and unmeasured confounders
increment in the counting process related to the event time at time t. Then λ(t) is more
precisely defined as E
{
dN(t)|T ≥ t, X¯(btc), U¯(btc), Z}. Consider the model
λ(t) = ω
{
t, U¯(btc)}+ βX(btc). (7.7)
The fact that the right hand side does not involve X¯(btc−1) embodies the assumption that early
exposures X¯(btc − 1) can only influence the hazard at time t by influencing the later exposure
X¯(btc). Making this assumption is partly a necessity, as the instrumental variable Z, which only
takes 3 levels in our motivating application, does not carry sufficient information to be able to
distinguish short-term from long-term exposure effects. Under the above assumptions (7.6) and
(7.7), along with specific conditions to be specified later, we will demonstrate that the following
estimating function for β
{M(t)− E [M(t)|T ≥ t]}R(t) {dN(t)− βM(t)dt} ,
where M(t) ≡ E {X(btc)|T ≥ t, Z}, is unbiased.
We will first investigate under what conditions, in addition to assumptions (7.6) and (7.7), the
generalised IV assumption
U(btc)⊥⊥Z|T ≥ s, U¯(btc − 1), (7.8)
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holds for all s ≥ btc. For this, note that, by Bayes’ rule, for each t and s ≥ t,
f(Z,U(btc)|T ≥ s, U¯(btc − 1)) = f(Z|T ≥ btc, U¯(btc − 1))f(U(btc)|T ≥ btc, U¯(btc − 1))
× P (T ≥ s|T ≥ btc, Z, U¯(btc))
P (T ≥ s|T ≥ btc, U¯(btc − 1)) ,
by assumption (7.6). Further, by assumption (7.7)
P (T ≥ t|T ≥ btc, Z, U¯(btc)) = exp
[
−
∫ t
btc
ω
{
s, U¯(btc)} ds] exp[−∫ t
btc
βM(s)ds
]
×E
{
exp
[
−
∫ t
btc
β∆(s)ds
]
|T ≥ btc, Z, U¯(btc)
}
,
which factorises as a product φz(t, Z)φu(t, U¯(btc)) when
∆(t)⊥⊥Z|T ≥ btc, U¯(btc). (7.9)
We conclude that (7.8) holds for s < btc + 1. By repeated averaging, it is moreover seen that
for btc+ 1 ≤ s < btc+ 2:
P (T ≥ s|T ≥ btc, Z, U¯(btc)) = P (T ≥ s|T ≥ btc+ 1, Z, U¯(btc))P (T ≥ btc+ 1|T ≥ btc, Z, U¯(btc))
= E
{
P (T ≥ s|T ≥ btc+ 1, Z, U¯(btc+ 1))|T ≥ btc+ 1, Z, U¯(btc)}
×P (T ≥ btc+ 1|T ≥ btc, Z, U¯(btc)).
Here, both terms P (T ≥ s|T ≥ btc + 1, Z, U¯(btc + 1) and P (T ≥ btc + 1|T ≥ btc, Z, U¯(btc))
can be written as a product of a function of t and Z, and a function of t and U¯(btc+ 1). Since
furthermore U(btc + 1)⊥⊥Z|T ≥ btc + 1, U¯(btc) by (7.6), this factorisation is maintained after
averaging, so that (7.8) also holds for btc+ 1 ≤ s < btc+ 2. Next, for btc+ 2 ≤ s < btc+ 3:
P (T ≥ s|T ≥ btc, Z, U¯(btc)) = P (T ≥ s|T ≥ btc+ 2, Z, U¯(btc))
×P (T ≥ btc+ 2|T ≥ btc+ 1, Z, U¯(btc))
×P (T ≥ btc+ 1|T ≥ btc, Z, U¯(btc)).
Let us concentrate on the first term; the other two are similar to earlier terms and enjoy the
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earlier factorisation. We have that
P (T ≥ s|T ≥ btc+ 2, Z, U¯(btc)) = E {P (T ≥ s|T ≥ btc+ 2, Z, U¯(btc+ 2))|T ≥ btc+ 2, Z, U¯(btc} .
Here, the term P (T ≥ s|T ≥ btc+2, Z, U¯(btc+2)) can be written as a product of a function of t
and Z, and a function of t and U¯(btc+2). Since furthermore U(btc+2)⊥⊥Z|T ≥ btc+2, U¯(btc+1)
by (7.6) and U(btc + 1)⊥⊥Z|T ≥ btc + 2, U¯(btc) by (7.8), this factorisation is maintained after
averaging, so that (7.8) also holds for btc + 2 ≤ s < btc + 3. Repeating along these lines, it is
seen that (7.8) holds for all s ≥ t.
Let us now revisit the unbiasedness of the estimating function under assumptions (7.7) and (7.8)
(which, by the above result, are implied by assumptions (7.6), (7.7) and (7.9)). This function
has expectation
E ({M(t)− E [M(t)|T ≥ t]}R(t) {dN(t)− βM(t)dt})
= E
({M(t)− E [M(t)|T ≥ t]}R(t) [ω {t, U¯(btc)} dt+ β∆(t)dt])
= E
({M(t)− E [M(t)|T ≥ t]}R(t)ω {t, U¯(btc)} dt) ,
where we make the testable assumption that ∆(t)⊥⊥Z|T ≥ t (which is implied by (7.9)).
We further have that
E
({M(t)− E [M(t)|T ≥ t]}R(t)ω {t, U¯(btc)} dt)
= E
({M(t)− E [M(t)|T ≥ t]}R(t)E [ω {t, U¯(btc)} |U¯(btc − 1), T ≥ t, Z])
= E
({M(t)− E [M(t)|T ≥ t]}R(t)E [ω {t, U¯(btc)} |U¯(btc − 1), T ≥ t])
= E
({M(t)− E [M(t)|T ≥ t]}R(t)ω∗ {t, U¯(btc − 1)}) ,
for some function ω∗(.), where we use that
U(btc)⊥⊥Z|T ≥ t, U¯(btc − 1).
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Continuing, working from the final display, we obtain that
E
({M(t)− E [M(t)|T ≥ t]}R(t)ω∗ {t, U¯(btc − 1)})
= E
({M(t)− E [M(t)|T ≥ t]}R(t)E [ω∗ {t, U¯(btc − 1)} |U¯(btc − 2), T ≥ t, Z])
= E
({M(t)− E [M(t)|T ≥ t]}R(t)E [ω {t, U¯(btc − 1)} |U¯(btc − 2), T ≥ t])
= E
({M(t)− E [M(t)|T ≥ t]}R(t)ω∗∗ {t, U¯(btc − 2)}) ,
for some function ω∗∗(.), where we use that
U(btc − 1)⊥⊥Z|T ≥ t, U¯(btc − 2).
Further continuing, we eventually obtain that the estimating function has expectation
E ({M(t)− E [M(t)|T ≥ t]}R(t)ω˜ {t, U(0)}) ,
for some function ω˜(.). Using that
U(0)⊥⊥Z|T ≥ t,
it is immediate that the latter expectation equals zero. A consistent estimator of β can thus be
obtained by solving an estimating equation based on the above estimating function. It follows
from Vansteelandt et al. (2014b) that the Aalen least squares estimator under model
λ˜(t) = ψ0(t) + βM(t)
solves precisely such equation, thus confirming the validity of the 2SPS estimator described in
Section 7.2.
7.3 Results
A total of 13080 observations or study visits were used to describe the time-varying exposure,
where 74% of the visits had exposure to ART (88%, 75% and 57% in the early, late integrated
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and sequential arms respectively).
Table 7.1: IV estimates for the effect of time-varying exposure on
mortality using additive hazards models
Univariable Multivariablea
Method/exposureb β 95% CI β 95% CI
As-treated -0.22 -0.30, -0.13 -0.21 -0.31, -0.13
2SPS -0.41 -0.72, -0.09 -0.29 -0.54, -0.03
a adjusted for gender, baseline CD4+ count and employment status
b measure of compliance defined as 1 at time t when the considered patient
was on ART at or prior to time t, and 0 otherwise
The IV analysis of time-varying exposure expresses a much higher effect of continuous ART
exposure versus no exposure (hazard difference of -0.29; 95% CI: -0.54 to -0.03) (Table 7.1). It
indicates that an average of 29 deaths were prevented for each year of follow-up in each 100
patients on (continuous) ART, compared with 100 patients not on ART, conditional on gender,
employment status and CD4+ cell count.
The large differences found between the estimated effects of fixed and time-varying exposures
are largely attributable to the different exposure definitions: compliance during TB treatment
was relatively good, resulting in clear differences in exposure distribution between the different
arms; however, since ART exposure was generally high for all patients outside the TB treatment
window, differences between the arms were much less pronounced in terms of the time-varying
exposure. A major drawback of our IV-methodology for time-varying exposures is that it relies
on a location-shift assumption, which is unlikely to hold for dichotomous exposures.
7.4 Model-based predicted survival probabilities
The model-based survival probabilities were estimated for values, 1 (on ART) and 0 (not on
ART) (Figure 7.2).
69
0 3 6 9 12 15 18 21 24
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Months after randomisation
P
re
d
ic
te
d
su
rv
iv
al
pr
ob
ab
ili
ty
X=1 X=0
Figure 7.2: Predicted survival curves from additive hazards model with time-varying exposure
The predicted survival probabilities for X = 1 in Figure 7.2 are higher than that of the early
integrated as seen in Figure 6.3. On the other hand, the predicted survival probabilities for a
patient without ART exposure, that is, X(t)=0 for all t, were very low compared to those for
X = 0 in Figure 6.3. X = 0 is obviously better than X(t)=0 because the former is an indication
of delayed ART (i.e. ART initiated after TB treatment completion), whereas the latter indicates
a patient who did not initiate ART at all.
7.5 Summary
In this Chapter, we extended the IV-methodology to time-varying measures of compliance. Our
analysis of time-varying exposure is based on novel IV-methodology which returns effects on the
additive hazard scale. We found that continuous use of ART averted on average of 29 deaths for
each year of follow-up in each 100 patients on (continuous) ART, compared with 100 patients not
70
on ART, conditional on gender, employment status and CD4+ cell count. The large differences
found between the estimated effects of fixed and time-varying exposures are largely attributable
to the different exposure definitions: while the analysis of a fixed exposure focus on the effect
on integration of ART and TB treatment (as compared to a regimen with delayed ART), the
analysis of a time-varying exposure focuses on the overall effect of continuous use of ART as
opposed to no ART at all. In contrast to G-estimation, it does have the drawback of making
assumptions on the distribution of the exposure (as shown in Equation 7.4). However, the pro-
posed methods can be applied using standard software and do not require specific corrections
for non-informative censoring.
We have already mentioned that the analysis of fixed exposure is less reliable because of the
previously mentioned concern for reverse causality, and the fact that differential ART exposure
outside the period of TB treatment may have induced a violation of the exclusion restriction
in this analysis. In contrast, also the time-varying IV analysis is subject to a violation of
the assumption that the residual in Equation (7.4) is (conditionally) uncorrelated with the in-
strumental variable. Even though this could be fixed by using the control function approach
(Tchetgen Tchetgen et al., 2015), it was shown to work for continuous exposures and unlikely
to hold for binary variables, more especially time-varying binary exposures.
We showed that the proposed IV approach for time-varying exposure is valid in the presence
of unmeasured time-varying confounders U(t), so long as these are not influenced by previous
exposure measurement X¯(t− 1), under the data-generating mechanism visualised in Figure 7.1.
While this is a potentially strong assumption, it is one that is implicit in all standard IV analyses
that reduce time-varying exposure to a fixed exposure, and one that is difficult or impossible to
relax. Indeed, without this assumption, there may be pathways from the instrumental variable
Z via X¯(t − 1) and U(t) towards the time-to-event endpoint, thereby inducing a dependence
between the instrumental variable and the unmeasured confounders, and thus violating the
instrumental variables assumptions.
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Chapter 8
Summary of results across different
analytical approaches
In order to ease a comparison between different analytical methods or approaches and regressions
models, it is helpful to restate different comparisons and also present a summary of the results.
This way it is easy to make sense of all the results from different chapters. Here, we present
results from semiparametric additive and Cox proportional hazards models under the ITT, “as
treated”and IV analyses. The following comparisons were made:
1. Results from semiparametric additive hazards models (equations 5.2, 6.2 and 7.5) are
presented in Table 8.1, where we compared hazard differences of
fixed exposure
a) randomisation arm (Z) under the ITT analyses
b) exposure (X) under the “as treated”analyses
c) exposure (Xˆ) under the IV analyses using both 2SPS and 2SRI approaches
time-varying exposure
d) exposure (X(t)) under the “as treated”analyses
e) exposure (Xˆ(t)) under the IV analyses using the 2SPS approach.
2. Results from semiparametric Cox proportional hazards models (equations 5.3 and 6.3) are
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presented in Table 8.2, where we compared hazard ratios of
a) randomisation arm (Z) under the ITT analyses
b) exposure (X) under the “as treated”analyses
c) exposure (Xˆ) under the IV analyses using both 2SPS and 2SRI approaches.
Table 8.1: ITT and IV estimates for the effect of study arm and exposure on
mortality using additive hazards models
Univariate Multivariatea
Method Arm/exposure type β 95% CI β 95% CI
ITT Early integrated -0.06 -0.11, -0.02 -0.05 -0.09, -0.01
Late integrated -0.06 -0.11, -0.02 -0.06 -0.11, -0.02
Sequential 0 0
As-treated X -0.12 -0.17, -0.08 -0.12 -0.17, -0.07
IV: 2SPS X -0.08 -0.14, -0.03 -0.07 -0.12, -0.01
IV: 2SRI X -0.06 -0.13, -0.01 -0.05 -0.11, 0.01
First-stage residuals -0.19 -0.35, -0.06 -0.23 -0.43, -0.09
As-treated X(t) -0.22 -0.30, -0.13 -0.21 -0.31, -0.13
IV: 2SPS X(t) -0.41 -0.72, -0.09 -0.29 -0.54, -0.03
a adjusted for gender, baseline CD4+ count and employment status
Table 8.2: ITT and IV estimates for the effect of study arm and exposure
on mortality using proportional hazards models
Univariable Multivariablea
Method Arm/exposure type HR 95% CI HR 95% CI
ITT Early integrated 0.44 0.25, 0.80 0.51 0.28, 0.92
Late integrated 0.46 0.26, 0.83 0.46 0.26, 0.83
Sequential 1.0 1.0
As-treated X 0.15 0.07, 0.31 0.14 0.06, 0.29
IV: 2SPS X 0.30 0.12, 0.70 0.35 0.14, 0.85
IV: 2SRI X 0.25 0.09, 0.64 0.26 0.09, 0.70
First-stage residuals 0.24 0.08, 0.71 0.18 0.05, 0.64
HR:hazard ratio
a adjusted for gender, baseline CD4+ count and employment status
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Chapter 9
Simulation study
We conducted a simulation study to investigate the potential bias from 2SPS and 2SRI ap-
proaches based on additive hazards models, where the instrument is a categorical variable with
three levels. The aim was to assess the robustness of the IV models and quantify the amount
of bias (if any) when using linear and binary exposures. In particular, when using time-varying
binary exposure, the two assumptions might not hold:
1. X(t) = E
{
X(t) | T ≥ t, Z}+ ∆(t)
2. ∆(t) is independent of Z given T ≥ t
For fixed exposures, Tchetgen Tchetgen et al. (2015) were able to circumvent this problem when
the instrumental variable is dichotomous; see also Martinussen et al. (2017b) for general instru-
mental variables. We used time-varying exposure in our analysis but only simulated datasets
with fixed exposures because the simulation of time-varying exposures is complex and therefore
was not performed. The R code for the simulation study is provided in Appendix 2.
Data was generated to mimic the SAPiT clinical trial structure. The variables were generated
in such way that exposure (X) was influenced by the study arm (Z) and failure times were
influenced by X alone or X and unmeasured confounders (U) as shown in Figure 2.1. Mea-
sured confounders were not included in the simulation study. Data were simulated for arbitrary
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strengths of the exposure effect on time-to-event outcome, such as low (βx between 0 and 0.3),
moderate (βx between 0.4 and 0.6) and large (βx > 0.7) effect. The aim was to determine
whether the amount of bias changes as the exposure effect becomes larger. The effect of un-
measured confounders on failure times and the sample size were kept constant as (βu=0.1) and
(N=1000) respectively. Sample size was kept constant because it has been shown elsewhere that
an increase in sample size does not have major impact in the magnitude of the bias (Li et al.,
2015). We simulated 1000 datasets for each scenario presented in Table 9.1.
Datasets for both linear and binary exposures were generated as follows:
1. Generate the instrumental variable Z (dummy coded), where each of the three study arm
forms one third of the total sample size.
2. Generate linear exposure X|Z=0.04 + 0.74Z1 + 0.34Z2+ε, where Z1 and Z2 represents
early and late integrated arms respectively and ε is an error term from normal with mean
0 and standard deviation 1. The values 0.74, 0.34 and 0.04 represent the mean exposure
in the early, late integrated and sequential arms respectively.
3. Generate binary exposure P (X = 1|Z) = expit(0.8Z1+0.5Z2), where 0.8 and 0.5 measures
an increase in log-odds of exposure for early and late integrated arms when compared to
the sequential arm.
4. Generate failure times using λ(t|X,Z) = λ0(t) + βxX, where the baseline hazard (λ0(t))
was allowed to vary under different exposure effects to avoid getting negative failure times.
The censoring took place at t = 2.0.
Using simulated data, we fitted additive hazards models under the 2SPS and 2SRI approaches.
We further assessed whether the inclusion of unmeasured confounders either exacerbates or
minimise bias (if any) in the 2SPS approach. Therefore, we generated data this way:
1. Generate U ∼ N(0, 1)
2. Linear exposure was generated as X|Z,U=0.04 + 0.74Z1 + 0.34Z2 + U
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3. Binary exposure was generated as P (X = 1|Z,U) = expit(0.8Z1 + 0.5Z2 + U)
4. Failure times were generated using λ(t|X,Z,U) = λ0(t)+βxX+βuU . The baseline hazard
(λ0(t)) was allowed to vary under different exposure effects to avoid getting negative failure
times and the censoring took place at t = 2.0. In the first stage, linear and logistic
regression were used for linear and binary exposure respectively.
Bias under each scenario was calculated as
1
1000
1000∑
j=1
(
θˆj − θ
)
.
Table 9.1: Average bias from 1000 simulations
Linear exposure Binary exposure
Sample Exposure Bias: Bias: Bias: Bias: Bias: Bias:
size effect (θ) 2SPS 2SRI 2SPSa 2SPS 2SRI 2SPSa
1000 0 0.0012 -0.0007 0.0043 0.0084 -0.0426 -0.0120
1000 0.05 0.0033 -0.0259 0.0235 -0.0036 -0.0214 0.0487
1000 0.1 -0.0023 0.0049 -0.0034 -0.0404 -0.0091 0.0538
1000 0.3 -0.0274 0.0960 -0.0200 -0.0449 0.0968 -0.0606
1000 0.5 0.0061 0.1975 -0.0159 0.0401 0.1961 -0.0515
1000 0.8 0.0214 0.3608 0.0308 -0.0339 0.3420 -0.0579
a 2SPS approach adjusted for unmeasured confounding
Results in Table 9.1 show that both linear and binary exposure performed well under 2SPS
approach even in the presence of unmeasured confounding. On the other hand, results from 2SRI
approach produced biased estimate especially when the exposure effect is moderate or larger.
These results suggest that the 2SPS approach is fairly robust when dichotomous exposures are
used. Even though our results show that the degree of bias for binary exposure is small under
these considered settings. However, we must warn the reader that no guarantees can be given
that the proposed approach for time-varying exposures is (nearly) unbiased when the exposure
is dichotomous, unless when the exposure effect is low.
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Chapter 10
Concluding remarks
In this thesis we focused on instrumental variables analysis to account for non-compliance in
an open label RCT which was designed to determine the optimal time to initiate ART in pa-
tients on tuberculosis treatment. We acknowledge that IV method can produce biased estimates
unless the instrumental variable meets the three crucial assumptions as well as the treatment
homogeneity assumption. Two of the three assumptions are untestable. The bias will be exacer-
bated when the instrument is weak. We showed that the testable IV assumption was met in our
analysis since the instrument was strong and evidently associated with the exposure (i.e. partial
F-statistics less ≥ 10) as shown in Table 6.2. The instrumental variable was randomised and
therefore exchangeability is guaranteed. We also showed that the instrumental variable was not
associated with measured confounders (Table 4.1) and therefore not expected to share common
causes with the time-to-event outcome.
The measure of compliance used in Chapter 6, focused on the level of TB and ART integration.
Non-compliance was as a result of patients not starting ART at correct time after TB treatment
initiation. Results from ITT and IV analyses were not very different and this was either due
to the fact that the level of non-compliance in the SAPiT trial was not very high or the issues
of reverse causality which affected the fixed exposure definition. Producing estimates that take
non-compliance to account is relevant in South African setting where TB and ART integration
remains an important topic due to a larger number of patients who are co-infected.
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In Chapter 7 we contributed to the IV literature by developing novel IV-methodology for time-
varying measure of compliance, which is currently lacking in IV research. As much as this was
applied using dichotomous exposure variable, it can be easily adapted to other exposure types.
One caveat about our novel IV approach is that it puts restriction on the exposure distribu-
tion which should be correctly specified, and therefore has to be modelled using the two-stage
method. In future, we plan to develop or apply (in case it is developed by then) an instrumen-
tal variables approach that incorporates time-varying exposure but does not require two-stage
modelling and thus avoid restrictions on the exposure distribution. While more reliable, the
analysis of time-varying exposure did not immediately allow us to assess the effectiveness of
ART treatment during the TB treatment window because the average TB duration was short
(i.e. on average six months). Furthermore, since the location-shift assumption is unlikely to hold
for this particular exposure, therefore we cannot exclude the possibility of large biases when the
exposure effect is large. It would be of interest to evaluate how the effect of time-varying ART
exposure is modified by TB treatment. This will require novel methodology to include interac-
tions between time-varying TB treatment and ART exposure in the model.
Some advances have been made in IV methodology for time-to-event outcomes including ours,
however most of those advances are built around additive hazards models. The Cox propor-
tional hazards model is the most popular and widely used regression for time-to-event data in
health research. However, the IV developments around this famous time-to-event regression
are very slow and we hope that recent work from Martinussen et al. (2017a) for IV under a
structural Cox model and that of MacKenzie et al. (2014) will stimulate more developments.
In the same breath, we hope this work will persuade statisticians in health research to utilise
additive hazards model in their analysis especially when the proportional hazards assumption
is violated. The advantage of using additive hazards models is that the hazard difference has
collapsibility properties compared to the hazard ratios. Basically, adjusting for variables that
are not associated with either the exposure or outcome should not change the hazard difference
but it can potentially change the magnitude of the hazard ratios. The interpretation of the
hazard difference is also straightforward because it gives an indication of how many cases will
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either be averted or detected depending on the nature of the time-to-event outcome, which can
be useful for public health planning and community interventions. The underutilisation of ad-
ditive hazards models was probably due the fact that for the longest time it could not be easily
applied in many statistical softwares other than in SAS using macros developed by Howell and
Kein (1998). Currently, additive hazards models including the application of our method can
be easily applied using the TIMEREG package in R, and hopefully its awareness will increase even
outside the IV topic.
In RCTs, “as-treated”, “safety”and “per-protocol”analyses are often used in conjunction with
the ITT analysis. Even though results from IV analysis should be interpreted with caution,
keeping in mind all the assumptions needed to render causal estimands, but we encourage RCTs
with non-compliance to also add IV analysis as part of the sensitivity or secondary analysis.
This will offer readers, patients and healthcare providers flexibility to choose an estimand that
resonate with them or their situations. The advantage of using IV analysis in this thesis was
that the randomisation arm was used as an instrument, whereas in non-randomisation studies
it is difficult to find an instrument. However, it was difficult to find a reliable exposure since we
did not have drug level data to confirm whether patients were actually taking their treatment
and moreover, adherent to it.
IV methods sometimes produce estimated treatment effect that may not be generalised to the
entire population when there is treatment effect heterogeneity. We note that our analysis infer
treatment effect in the treated, and thereby assume treatment effect homogeneity (i.e. patients
with a given ART exposure level on the different arms on average experience the same benefit
of it). We do not infer the effect in compliers, as this would be more difficult to define with a
time-varying and/or continuous measure of compliance. We are moreover concerned about the
usefulness of inferring treatment effects for a subgroup of individuals that we cannot identify.
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Background: Using intent-to-treat comparisons, it has been shown 
that the integration of antiretroviral therapy (ART) and tuberculo-
sis (TB) treatment improves survival. Because the magnitude of the 
effect of ART initiation during TB treatment on mortality is less well 
understood owing to noncompliance, we used instrumental variables 
(IV) analyses.
Methods: We studied 642 HIV-TB co-infected patients from the 
Starting Antiretroviral Therapy at Three Points in Tuberculosis trial. 
Patients were assigned to start ART either early or late during TB 
treatment or after TB treatment completion. We used 2-stage pre-
dictor substitution and 2-stage residuals inclusion methods under 
additive and proportional hazards regressions with a time-fixed mea-
sure of compliance defined as the fraction of time on ART during 
TB treatment. We moreover developed novel IV methods for additive 
hazards regression with a time-varying measure of compliance.
Results: Intent-to-treat results from additive hazards models showed 
that patients in the early integrated arms had a reduced hazard of 
˗0.05 (95% confidence interval [CI]: ˗0.09, ˗0.01) when compared 
with the sequential arm. Adjustment for noncompliance changed this 
effect to ˗0.07 (95% CI: ˗0.12, ˗0.01). An additional time-varying IV 
analysis on the overall effect of ART exposure suggested an effect of 
˗0.29 (95 % CI: ˗0.54, ˗0.03).
Conclusion: IV analyses enable assessment of the effectiveness of 
TB and ART integration, corrected for noncompliance, and thereby 
enable a better public health evaluation of the potential impact of this 
intervention.
Keywords: Additive hazards model; Instrumental variable; Noncom-
pliance; Time-varying exposure; HIV; TB
(Epidemiology 2019;30: 197–203)
In 2014, an estimated 1.2 million people were co-infected with tuberculosis (TB) and HIV, around 74% of them living 
in sub-Saharan Africa.1 In some parts of South Africa, it is 
estimated that almost 70% of TB patients are co-infected with 
HIV.2 South Africa has the largest antiretroviral therapy (ART) 
roll-out programme with approximately 3 million people on 
ART in 2015.3 Despite the size of the ART roll-out and wide 
availability of TB treatment, TB and HIV are reported to be 
the leading causes of death in South Africa in the age group 
15–44 years.4
Initiation of ART within 4 weeks after the start of TB 
therapy or within 4 weeks after the completion of the intensive 
phase of TB therapy has been shown to improve survival,5,6 
especially among patients with low CD4+ cell count.7,8 In 
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South Africa, TB patients were the first ones to be initiated 
on ART irrespective of their CD4+ cell count.9 Patients who 
develop TB while on ART should continue with ART through-
out TB therapy duration. One of the studies that informed 
guidelines on treatment integration was the Starting Antiret-
roviral Therapy at Three Points in Tuberculosis (SAPiT) trial. 
SAPiT was an open-label randomized controlled trial where 
patients were randomly assigned to start ART either early or 
late during TB treatment or after the completion of  TB therapy. 
Irrespective of the randomization arm, patients in the SAPiT 
study could be started on ART at any time by study clinicians 
or personal physicians at their discretion. In the current analy-
ses, noncompliance is defined as not starting ART at the cor-
rect time with respect to TB treatment, regardless of whether 
that was enforced by clinicians or by patients themselves.
However, this definition of noncompliance does not 
take into account any temporary or permanent discontinua-
tion of study drugs and adherence. Among the 362 patients 
who initiated ART in early and late integrated arms of the 
SAPiT trial, 22.4% did not initiate ART at the correct time.8 
Moreover, following recommendations by data and safety 
monitoring committee, some patients started ART ear-
lier than the protocol specified time5 and are regarded as 
noncompliant.
To preserve the balance brought about by randomiza-
tion, intent-to-treat (ITT) comparison was used for the pri-
mary analyses of the trial. This provides valid estimates of the 
effect of randomized assignment, but likely underestimates 
the effectiveness of treatment integration in the presence of 
noncompliance. To adjust for noncompliance, “as-treated” 
and “per-protocol” comparisons are commonly made. These 
contrast study participants according to their received treat-
ment, regardless of the treatment arm to which they were 
assigned, or limit the analysis to participants who followed 
the protocol. Such analyses are generally biased because the 
subgroups that they compare often lack comparability.
In view of the shortcomings of the “as-treated” and 
“per-protocol” analyses, our objective was to account for 
noncompliance by using instrumental variables (IV) analyses 
to estimate the effect of ART initiation during TB treatment 
(exposure) on mortality. This will also be referred to as effec-
tiveness. IV analyses enable us to make use of the comparabil-
ity offered by randomization and thereby have the capability 
of adjusting for unmeasured and measured confounders; they 
have the further advantage of yielding results that are less sen-
sitive to random measurement error in the exposure.10 The key 
challenge with IV analyses especially in nonrandomized stud-
ies is obtaining a valid instrument, which must (1) be associ-
ated with an exposure; (2) only affect the outcome through 
its association with an exposure; and (3) not share common 
causes with an exposure. We used randomization arm as an 
instrument, with the exposure being defined as the fraction 
of time on ART during TB treatment (i.e., months on ART/
months on TB therapy).
A limitation of using such fixed exposure over time 
is that it cannot capture the full complexity of compliance 
behavior and may, moreover, be indirectly influenced by cen-
soring or death. In view of this, we also provide analyses for a 
time-varying measure of compliance to ART. IV-methodology 
for the effect of a time-varying exposure on a time-to-event 
endpoint is currently lacking, with the exception of G-estima-
tion for structural accelerated failure time models.11 Because 
this is complex and often performs poorly in the presence of 
censoring, we developed novel methodology under so-called 
additive hazard models. The proposed methods can be applied 
using standard software and do not require specific correc-
tions for noninformative censoring.
METHODS
Dataset
This analysis is based on 642 HIV-TB co-infected 
patients from the SAPiT open-label randomized trial that was 
conducted between June 2005 and July 2010 in South Africa. 
The primary objective of the trial was to determine the opti-
mal timing of ART initiation in patients co-infected with HIV 
and TB. More details about the study and the results for pri-
mary and secondary outcomes have been published in detail 
elsewhere.5,8,12,13
Patients who had confirmed HIV infection and newly 
diagnosed pulmonary TB were randomly assigned to start 
ART at the following 3 different points of their TB therapy. In 
the first arm, ART was to be initiated within 4 weeks after the 
start of TB therapy (early integrated arm). In the second arm, 
ART was to be initiated within 4 weeks after the completion 
of the intensive phase of TB therapy (late integrated arm). In 
the third arm, ART was to be initiated within 4 weeks after 
the completion of TB therapy (sequential arm). All patients 
received prophylaxis to control opportunistic infections. After 
a planned interim analysis, on September 1, 2008, almost 2 
months after completion of enrollment, the data and safety 
monitoring committee made a recommendation that all 
patients in the sequential arm be initiated on ART as soon 
as possible but stay in follow-up until study completion. The 
committee also recommended continuation of the early and 
late integrated arms without any modifications.
The SAPiT study was approved by the Biomedical 
Research Ethics Committee of the University of KwaZulu-
Natal (E107/05) and the Medicines Control Council of South 
Africa (20060157).
Exposure
As mentioned earlier, the fixed exposure, denoted by 
X, is defined as the fraction of time on ART during TB treat-
ment (i.e., months on ART/months on TB therapy) (Figure 1). 
This was defined regardless of how long patients were on TB 
treatment (as some took more than the expected 6 months to 
complete TB treatment). Patients who were terminated before 
initiating ART were assigned an exposure of zero.
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The rationale for choosing this exposure is as follows. 
In South Africa, TB and HIV are the leading causes of death 
in adults,4 and TB-HIV co-infected patients are supposed to 
be co-treated by the same healthcare worker for both diseases. 
However, in resource-poor countries like South Africa, this 
integration has not been fully implemented. Among other 
things, one constraint is the low uptake of HIV testing among 
TB patients that deprive patients of treatment integration.1 For 
these reasons, this article focuses on strengthening the evi-
dence of the benefit of integrated therapy on mortality. Our 
IV analysis based on this exposure will express how, under 
perfect compliance, the ITT-analysis comparing the early inte-
grated arm (where the exposure is then 1) and the sequential 
arm (where the exposure is then 0) would have fallen out.
Owing to the above-explained limitations of a fixed 
exposure over time, we have moreover developed IV-meth-
odology for a time-varying measure of compliance to ART, 
which we defined as 1 at time t when the considered patient 
was on ART at or before time t, and 0 otherwise. Our IV anal-
ysis based on this exposure will express the effect of continu-
ous ART use versus no ART use (regardless of TB treatment).
Outcome
We will focus on all-cause mortality. The survival time 
was defined as time from randomization until the date of 
death. It was censored at the withdrawal date, last visit date 
for those who were loss to follow-up or date of the 24-month 
visit for those who completed the study.
Covariates
The association between the fraction of time on ART 
during TB treatment and all-cause mortality is confounded 
because patients in poorer conditions (e.g., with lower CD4+ 
count) were at higher risk of death and thus more likely to 
initiate ART early irrespective of the study arm. Although the 
considered IV analysis do not require adjustment for mea-
sured confounders, we considered adjustment for CD4+ cell 
count, sex (0 = male; 1 = female) and employment status (0 = 
unemployed; 1 = employed) to improve precision. The instru-
ment Z (0 if assigned to sequential arm, 1 if assigned to late 
integrated arm and 2 if assigned to early integrated arm). This 
was modeled categorically.
Statistical Analysis of Fixed Exposure
We first performed ITT analyses based on additive haz-
ards models and Cox proportional hazards models. These 
assess the association between assignment Z to one of the 
arms and all-cause mortality. To investigate the association 
between the exposure X and all-cause mortality, we next per-
formed IV analyses.
In particular, we used 2-stage predictor substitution 
(2SPS) and 2-stage residuals inclusion (2SRI) methods. Two-
stage predictor substitution is a nonlinear extension of the lin-
ear 2-stage least squares. Two-stage residuals inclusion was 
first introduced by Hausmann14 and recently proposed for the 
analysis of time-to-event endpoints by Terza et al.15 Both these 
approaches work by fitting, in a first-stage, univariable or mul-
tivariable linear regression models of the association between 
X and Z. For instance, our results below are based on the mul-
tivariable model:
 X Zz m
T
= + + +α α α ε0 M  (1)
where M is vector of measured covariates such as sex, employ-
ment status, and CD4+ cell count and where Z was modeled 
categorically (using dummy coding). The 2-stage predictor 
substitution approach then proceeds by regressing the survival 
time on the fitted values Xˆ  from the first-stage regression (1) 
and on the measured covariates M either using additive hazard 
or Cox proportional hazards regression models. The 2-stage 
residuals inclusion approach proceeds likewise, but regressing 
additionally on the residuals X-Xˆ  from the first-stage regres-
sion (1).
Tchetgen Tchetgen et al.16 showed that, under certain 
conditions specified next, the coefficient of Xˆ  in the result-
ing additive hazard model can be interpreted as the exposure 
effect βx in the additive hazard model
 λ λ β β βt X U Z t X t Ux mT u| , , , M M( ) = ( ) + + + ( )0  (2)
which involves adjustment for possible unmeasured confound-
ers U. Here, exp (˗βxt) can be interpreted as the relative chance 
of surviving time t with exposure 1 vs 0; note that it takes the 
length of the exposure period into account via. the value of t. 
For the 2-stage predictor substitution approach, the condition 
is that the error term ε  in the exposure model (1) is indepen-
dent of randomization arm (given the covariates M). For the 
2-stage residuals inclusion approach, a more subtle additional 
assumption is needed, which is satisfied when the error term 
ε  equals the unmeasured confounder U apart from (additive) 
random noise. Because tests of the null hypothesis of no expo-
sure effect are robust against model misspecification in the 
Early Late Sequential 
0.0
0.2
0.4
0.6
0.8
1.0
Ex
po
su
re
(A
R
T/
TB
du
ra
tio
n)
Randomization arm
FIGURE 1. Exposure (fraction of time on ART during TB 
treatment) in the 3 randomized arms.
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2-stage predictor substitution approach (unlike the 2-stage 
residuals inclusion approach), we generally recommend the 
predictor substitution approach. Both these approaches can be 
extended to Cox proportional hazard models when the event 
(all-cause mortality) is rare, which is not well satisfied in the 
SAPiT trial. Under the rare assumption, then the coefficient 
of Xˆ  can be interpreted as the exposure effect βx in the Cox 
proportional hazards regression model
 λ λ β β βt X Z U t X Ux mT u| , , , exp ,M M( ) = ( ) + +( )0  (3)
but not otherwise.
We calculated model-based survival probabilities for 
ITT and IV analyses under the 2SPS approach of the addi-
tive and proportional hazards models. In the IV analyses, the 
survival probabilities were estimated for 3 fixed exposure lev-
els of 0 (no exposure), 0.6 (partial exposure), and 1.0 (full 
exposure). These correspond to what the survival probabilities 
would have looked like in the sequential, late, and early inte-
grated arms, respectively, had there been perfect compliance.
Standard errors reported below are based on 1,000 non-
parametric bootstrap samples with replacement, refitting both 
stages of the procedure each time. We used the bias-corrected 
and accelerated method17 to calculate 95% confidence inter-
vals (CIs) for βx in the second-stage.
Statistical Analysis of Time-varying Exposure
In view of the aforementioned limitations of using a 
fixed exposure over time, we next extended the 2-stage pre-
dictor substitution approach to time-varying measures X(t) 
of compliance (see eAppendix 1; http://links.lww.com/EDE/
B410). Our results are based on the multivariable model
 X t t t Z t tz m
T( ) = ( ) + ( ) + ( ) + ( )α α α ε0 M  (4)
defined for patients who are alive at time t, which we consider 
at each observed event time t. Under the assumption that ε t( ) 
is uncorrelated with Z, conditional on M  for patients who are 
alive at time t, we then show in the eAppendix 1; http://links.
lww.com/EDE/B410 that the 2-stage predictor substitution 
approach can be extended to an additive hazard regression of 
the survival time on the fitted values Xˆ t( ) from the first-stage 
regression (4) (which is limited to patients who are alive at 
time t) and on the measured covariates M. In particular, we 
show that the resulting effect βx of Xˆ t( ) can be interpreted as 
the effect of X(t) in the additive hazard model
λ λ β β βt X t U Z t X t t Ux mT u|
− ( )  = ( ) + ( ) + + ( ), , ,M M0  (5)
It follows from the eAppendix 2; http://links.lww.com/EDE/
B410 that the proposed IV approach for time-varying exposure is 
valid in the presence of unmeasured time-varying confounders, 
U(t), so long as these are not influenced by previous exposure 
measurement X t −( )1 ; that is, under the data-generating mecha-
nism visualized in eFigure 1; http://links.lww.com/EDE/B410. 
Although this is a potentially strong assumption, it is one that 
is implicit in all standard IV analyses that reduce time-varying 
exposure to a fixed exposure, and one that is difficult or impos-
sible to relax. Indeed, without this assumption, there may be 
pathways from the instrumental variable Z via. X t −( )1  and U(t) 
toward the time-to-event endpoint, thereby inducing a depen-
dence between the IV and the unmeasured confounders, and thus 
violating the IVs assumptions.
We calculated model-based survival probabilities under 
the proposed additive hazards models for values, 1 (on ART) 
and 0 (not on ART). Statistical analyses were done using SAS 
version 9.4 (SAS Institute Inc., Cary, NC) and R version 3.2.4.
RESULTS
Baseline and Follow-up
A total of 642 patients were enrolled: 214 in the early 
integrated arm, 215 in the late integrated arm, and 213 in the 
sequential arm (eFigure 2; http://links.lww.com/EDE/B410). 
Patients in the 3 study arms had similar baseline demographic 
and clinical characteristics (eTable 1; http://links.lww.com/
EDE/B410).
During a median follow-up of 24 months (interquartile 
range, 10.5–24 months), 69 (10.7%) patients died (17 in each 
of the early and late integrated arms and 35 in the sequen-
tial arm). A total of 417 (65.0%) completed the study (early 
integrated arm [n = 151], late integrated arm [n = 139], and 
sequential arm [n = 127]). A total of 96 (15.0%) were lost to 
follow-up (early integrated arm [n = 26], late integrated arm 
[n = 36], and sequential arm [n = 34]); while 60 (9.3%) either 
withdrew consent or relocated to other areas (early integrated 
arm [n = 20], late-integrated arm [n = 23], and sequential arm 
[n=17]). A total of 16 (7.5%), 51 (23.7%), and 74 (34.7%) 
patients did not start ART in the early, late-integrated, and 
sequential arms, respectively, owing to reasons such as death, 
loss to follow-up, relocation, and voluntarily withdrawal 
(eFigure 2; http://links.lww.com/EDE/B410). The baseline 
and clinical characteristics by study arm are presented in 
eTable 1; http://links.lww.com/EDE/B410, whereas the char-
acteristics of the compliant and noncompliant patients in all 
arms are shown in eTable 2; http://links.lww.com/EDE/B410.
Over 984.79 person–years of follow-up, the mortality rates 
were 4.9 per 100 person–years (py) (95% CI: 2.9, 7.9) in the early 
integrated, 5.2 per 100 py (95% CI: 3.0, 8.2) in the late integrated, 
and 11.3 per 100 py (95% CI: 7.9, 15.8) in the sequential arm.
The median (interquartile range) duration on TB treat-
ment was 6.7 (6.4–8.3) months in each of the 3 study arms. 
The mean exposure to ART during TB treatment was 0.78 in 
the early integrated, 0.39 in the late integrated, and 0.04 in the 
sequential arm (Table 1, Figure 1).
Additive Hazards Analysis on the Effect of 
Integrating ART and TB Treatment
Multivariable results from ITT analyses showed that 
patients in the early and late integrated arms had a hazard 
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difference of ˗0.05 (95% CI: ˗0.09, ˗0.01) and ˗0.06 (95% CI: 
˗0.11, ˗0.02), respectively, when compared with the sequen-
tial arm. This indicates that on average, 5 and 6 deaths were 
averted for each year of follow-up in each 100 patients ran-
domly assigned to early and late integrated arms compared 
with each 100 patients in the sequential arm (Table 2).
The 2-stage predictor substitution analysis of the fixed 
exposure showed that on average, 7 deaths (hazard difference 
= ˗0.07; 95% CI: ˗0.12, ˗0.01) were prevented for each year 
of follow-up in each 100 patients with full exposure to ART 
during TB treatment (as would be the case under perfect com-
pliance in the early integrated arm) as opposed to 100 patients 
with no ART exposure during TB treatment (as would be the 
case under perfect compliance in the sequential arm) (Table 2). 
The 2-stage residual inclusion method for the fixed exposure 
resulted in slightly weaker effects (hazard difference = ˗0.05; 
95% CI: ˗0.11, 0.01). The strong association found between 
the first-stage residuals and time to death in this analysis pro-
vides strong evidence of unmeasured confounding, which the 
IV-analysis accounted for. The findings from the “as-treated” 
analyses of the fixed exposure (hazard difference = ˗ 0.12; 95% 
CI: ˗0.17, ˗0.07) are thus likely biased (Table 2). Results from 
proportional hazards regression are shown in the Web Appen-
dix (eTable 6; http://links.lww.com/EDE/B410).
Figure 2A shows model-based predicted survival proba-
bilities from univariable ITT and IV (fixed exposure) analyses 
under the 2-stage predictor substitution approach from addi-
tive hazards model. Figure 2B shows predicted survival prob-
abilities obtained from the model with time-varying exposure. 
The survival probabilities for X = 1 in both figures are higher 
than that of the early integrated arm. However, survival prob-
abilities for X = 0.6 and X = 0 are closer to those for late 
integrated and sequential arms, respectively (Figure 2A). Pre-
dicted survival probabilities under proportional hazards mod-
els are shown in eFigures 3A and 3B; http://links.lww.com/
EDE/B410.
Time-varying Additive Hazards Analysis on the 
Effect of ART
The IV-analysis of time-varying ART exposure expresses 
the effect of continuous ART exposure versus no exposure 
(hazard difference of ˗0.29; 95% CI: ˗0.54, ˗0.03) (Table 2). It 
indicates that an average of 29 deaths were prevented for each 
year of follow-up in each 100 patients on (continuous) ART, 
compared with 100 patients not on ART, conditional on sex, 
employment status, and CD4+ cell count. Corresponding pre-
dicted survival probabilities for a patient without ART expo-
sure, X(t) = 0 for all t, were very low (Figure 2B). The large 
differences found between the estimated effects of fixed and 
TABLE 1. First-stage Linear Regression Model Predicting the 
Fixed Exposure
Effect
Univariable Multivariablea
Estimate S.E. Estimate S.E.
Intercept 0.04 0.02 0.06 0.03
Early integrated arm 0.74 0.02 0.74 0.02
Late integrated arm 0.35 0.02 0.35 0.02
Sequential arm 0  0  
F-value; partial R2 514.68; 0.62 211.66; 0.62
aAdjusted for sex, baseline CD4+ count, and employment status.
S.E., standard error.
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FIGURE 2. Predicted survival curves comparing ITT and IV estimates from additive hazards model (A: fixed exposure, B: time-
varying exposure).
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time-varying exposures are largely attributable to the different 
exposure definitions: while the analyses of a fixed exposure 
focus on the effect of integration of ART and TB treatment (as 
compared with a background regimen with ART), the analysis 
of a time-varying exposure focuses on the overall effect of 
ART. Arguably, the analysis of fixed exposure is also less reli-
able because of the previously mentioned concern for reverse 
causality, and the fact that differential ART exposure outside 
the period of TB treatment may have induced a violation of the 
exclusion restriction in this analysis. In contrast, also the time-
varying IV analysis is subject to a violation of the assumption 
that the residual in equation (4) is (conditionally) uncorrelated 
with the IV.
This location shift assumption could be plausible for 
continuous exposures, but is known to be violated for dichoto-
mous exposures. In view of this, we report the results of lim-
ited simulation studies for time-fixed exposures in eTable 7; 
http://links.lww.com/EDE/B410. These show that the degree 
of bias under violation of this assumption is small under the 
considered settings. However, we must warn the reader that 
we cannot guarantee that the proposed approach for time-
varying exposures is (nearly) unbiased when the exposure is 
dichotomous, unless when the exposure effect is close to, or 
equal to zero.
DISCUSSION
We have provided IV analyses of the causal effect of 
exposure to ART (during TB treatment) on time to death, to 
account for noncompliance as a result of not all patients adher-
ing to randomization and starting ART at the correct time 
with respect to TB treatment. The SAPiT trial data have been 
analyzed using ITT methods and showed that integration of 
ART and TB treatment saves lives.5 Our results express more 
precisely how many lives could be saved under perfect com-
pliance. The IV results thus appeal to patients and clinicians 
who are interested in the benefits of initiating and adhering to 
received treatment. The results from the “as-treated” analyses 
showed even higher effectiveness, but these results are biased 
because patients who comply and those who do not comply 
with the randomized treatment are not always comparable.
The analyses were carried out using the semiparamet-
ric additive hazards models. Cox proportional hazards models 
were used for comparison. Our instrumental variables analy-
sis relies on 2 key assumptions. The first, that patients on the 
different arms of the study are exchangeable, is guaranteed 
by randomization. The second, so-called exclusion restriction, 
that randomized assignment may only influence all-cause mor-
tality by changing ART exposure, could be violated. One pos-
sible cause of violation concerns our definition of exposure, 
which may not fully capture all relevant components such as 
adherence, which could have an effect on mortality. A second 
possible reason is that, in the open-label SAPiT trial, being 
assigned to either of the integrated arms may have enhanced 
patient’s expectation of success, and in contrast, assignment to 
the sequential arm might have reduced such an expectation. 
Moreover, those randomized to integrated arms who did not 
start ART soon after TB treatment initiation might have delib-
erately delayed ART initiation because they were still feeling 
well and did not see the need to integrate TB treatment and 
ART. Our analysis moreover ignored differential ART expo-
sure outside the TB treatment window. All of this, in turn, vio-
lates the exclusion restriction assumption, which underlies our 
analysis. The violation of this untestable assumption can lead 
to biased IV estimates.
We acknowledge several additional limitations in our 
analyses. Our fixed exposure did not differentiate between 
patients who were on TB treatment for 6 months and those 
who were on TB treatment for a longer period. A patient who 
was on TB treatment for 6 months and only took ART for 3 
months had similar exposure level to a patient who was on 
TABLE 2.  ITT and IV Estimates for the Effect of Study Arm and Exposure on Mortality Using Additive Hazards Models
Method/Exposure Arm/Exposure type
Univariable
β (95% CI)
Multivariablea
β (95% CI)
ITT Early integrated arm ˗0.06 (˗0.11, ˗0.02) ˗0.05 (˗0.09, ˗0.01)
 Late integrated arm ˗0.06 (˗0.11, ˗0.02) ˗0.06 (˗0.11, ˗0.02)
 Sequential arm 0 0
Time-varying exposure
 As-treat Exposure to ART during follow-up ˗0.22 (˗0.30, ˗0.13) ˗0.21 (˗0.31, ˗0.13)
 2SPS Exposure to ART during follow-up ˗0.41 (˗0.72, ˗0.09) ˗0.29 (˗0.54, ˗0.03)
Fixed exposure
 As-treated Exposure to ART during TB treatment ˗0.12 (˗0.17, ˗0.08) ˗0.12 (˗0.17, ˗0.07)
 2SPS Exposure to ART during TB treatment ˗0.08 (˗0.14, ˗0.03) ˗0.07 (˗0.12, ˗0.01)
 2SRI Exposure to ART during TB treatment ˗0.06 (˗0.13, ˗0.01) ˗0.05 (˗0.11, 0.01)
First-stage residuals ˗0.19 (˗0.35, ˗0.06) ˗0.23 (˗0.43, ˗0.09)
aAdjusted for sex, baseline CD4+ count, and employment
2SRI, 2-stage residuals inclusion.
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TB treatment for 12 months and took ART for 6 months. The 
latter patient is more likely to have drug-resistant TB and thus 
be more likely to die. Also, for patients who died soon after 
enrollment and those who did not start ART, the exposure is 
not ideally defined. We have tried to counteract that limitation 
by developing an IV-methodology for a time-varying measure 
of compliance. This analysis answers a different scientific 
question, but better recognizes the complexity of the expo-
sure. Indeed, the magnitude of a summary exposure over the 
observation period is likely influenced by censoring owing to 
loss to follow-up, and death, and therefore ill defined. In par-
ticular, while more reliable, the analysis of time-varying expo-
sure did not immediately allow us to assess the effectiveness 
of ART treatment during the TB treatment window.
However, a drawback of our IV-methodology for time-
varying exposures is that it relies on a location-shift assump-
tion, which is unlikely to hold for dichotomous exposures. 
For such exposures, we cannot exclude the possibility of large 
biases when the exposure effect is large. For time-fixed expo-
sures, Tchetgen Tchetgen et al.16 were able to circumvent this 
problem when the instrument is dichotomous; see also Marti-
nussen et al.18 for general IVs. It is an open question whether 
their proposals can be extended to time-varying exposures.
Our analysis of time-varying exposure is based on novel 
IV-methodology that returns effects on the additive hazard scale. 
Although alternative G-estimation strategies have been pro-
posed to infer the effect of a time-varying exposure on a time-
to-event endpoint in the presence of an IV under an alternative 
class of structural accelerated failure time models,11 application 
of these methods in applied research has been relatively infre-
quent because of their complexity and often poor performance 
in the presence of censoring.19 Our proposal overcomes these 
concerns by being applicable in standard software for additive 
hazard models, which naturally accommodates noninformative 
censoring without requiring further adjustments. In contrast to 
G-estimation, it does have the drawback of making assumptions 
on the distribution of the exposure (as shown in model (4)).
Further, our analyses infer a treatment effect in the 
treated, and thereby assume treatment effect homogeneity 
(i.e., that patients with a given ART exposure level on the dif-
ferent arms on average experience the same benefit of it). We 
do not infer the effect in compliers, as this would be more dif-
ficult to define with a time-varying and/or continuous measure 
of compliance. Finally, we assumed that censoring is nonin-
formative, given the covariates that we controlled for, and is 
moreover independent of the exposure and IV.
In conclusion, results from IV analyses demonstrate that 
survival benefit of fully integrating TB treatment and ART is 
even higher than what has been reported in the ITT analyses 
since noncompliance has been accounted for. IV estimates 
are clinically important because knowing the effectiveness of 
the TB and ART integration in the absence of noncompliance 
enables a much better public health evaluation of the potential 
impact of this intervention.
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Appendix 2: R code
2SPS and 2SRI approach using fixed continuous exposure
install.packages("timereg")
library(timereg)
# stage 1: univariable linear model
unilin <- lm(exposure ∼ factor(dummy1)+factor(dummy2), data=mydata)
summary (unilin)
#get predicted values
mydata$preduni <- predict(unilin)
#get residuals
mydata$resuni <- residuals(unilin)
# stage 2: univariable additive hazards model under 2SPS
uni sps <- aalen(Surv(Yearz, Died==1) ∼ const(preduni), robust=0, data=mydata)
summary(uni sps)
# stage 2: univariable additive hazards model under 2SRI
uni sri <- aalen(Surv(Yearz, Died==1) ∼ const(exposure)+const(resuni), robust=0,
data=mydata)
summary(uni sri)
#bootstrap get standard errors and confidence intervals
i<-0
98
nuke.fun <- function(data, indices)
{
dat<-data[indices,]
unilin <- lm(exposure ∼ factor(dummy1)+factor(dummy2), data=dat)
dat$preduni<-NA
dat$resuni<-NA
dat$preduni <-predict(unilin)
dat$resuni <-residuals(unilin)
uni sps <-aalen(Surv(Yearz, Died==1) ∼ const(preduni), robust=0, data=dat)
uni sri <-aalen(Surv(Yearz, Died==1) ∼ const(exposure)+ const(resuni), robust=0,
data=dat)
c(coef.aalen(uni sps)[,1],coef.aalen(uni sri)[,1])
}
nuke.boot <- boot(mydata,nuke.fun, R = 1000)
# median
vv <-apply(nuke.boot$t,2, median)
# get confidence intervals
boot.ci(nuke.boot, type=c("bca"), index=1, conf=0.95) #2SPS
boot.ci(nuke.boot, type=c("bca"), index=2, conf=0.95) #2SRI
boot.ci(nuke.boot, type=c("bca"), index=3, conf=0.95) #2SRI
# stage1: multivariable linear model
multilin <- lm(exposure ∼ factor(dummy1)+factor(dummy2)+const(CD4count)+
const(Gender)+const(Employ), data=mydata)
summary (multilin)
#get predicted values
mydata$predmulti <- predict(multilin)
#get residuals
mydata$resmulti <- residuals(multilin)
#stage 2: multivariable additive hazards model under 2SPS
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multi sps <- aalen(Surv(Yearz, Died==1) ∼ const(predmulti)+const(CD4count)+
const(Gender)+const(Employ), robust=0, data=mydata)
summary(multi sps)
#stage 2: multivariable additive hazards model under 2SRI
multi sri <- aalen(Surv(Yearz, Died==1) ∼ const(exposure)+const(resmulti)+
const(CD4count)+ const(Gender)+const(Employ), robust=0, data=mydata)
summary(multi sri)
#bootstrap get standard errors and confidence intervals
i<-0
nuke.fun <- function(data, indices)
{
dat<-data[indices,]
multilin <- lm(exposure ∼ factor(dummy1)+factor(dummy2)+const(CD4count)+
const(Gender)+const(Employ), data=dat)
dat$predmulti<-NA
dat$resmulti<-NA
dat$predmulti <-predict(multilin)
dat$resmulti <-residuals(multilin)
multi sps <-aalen(Surv(Yearz, Died==1) ∼ const(predmulti)+const(CD4count)+
const(Gender)+const(Employ), robust=0, data=dat)
multi sri <-aalen(Surv(Yearz, Died==1) ∼ const(exposure)+ const(resmulti)+
const(CD4count)+ const(Gender)+const(Employ), robust=0, data=dat)
c(coef.aalen(multi sps)[,1],coef.aalen(multi sri)[,1])
}
# median
nuke.boot <- boot(mydata,nuke.fun, R = 1000)
vv <-apply(nuke.boot$t,2, median)
# get confidence intervals
boot.ci(nuke.boot, type=c("bca"), index=1, conf=0.95) #2SPS
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boot.ci(nuke.boot, type=c("bca"), index=5, conf=0.95) #2SRI
boot.ci(nuke.boot, type=c("bca"), index=6, conf=0.95) #2SRI
2SPS approach using time-varying binary exposure
# univariable
# time is ordered time-points (t)
# yrlast is observed failure times (T)
# start yr is the start of the time interval
# stop yr is the stop of the time interval
# rx is the binary exposure
# Calculating E(X(t) | Z, T ≥ t)
time <- sort(unique(c(longdata$start yr,longdata$stop yr)))
longdata$xmean <- NULL
for (i in 1:length(time)){
mod <- glm(rx ∼ dummy1+dummy2, family="binomial", data = longdata,
subset = (longdata$yrlast >= time[i]))
longdata$xmean[longdata$stop yr == time[i]] <-
predict(mod,newdata=longdata[longdata$stop yr == time[i],],type="response")
}
# second stage additive hazards model
unilong<-aalen(Surv(start yr,stop yr, fdied==1) ∼ const(xmean),robust=0,
data=longdata)
summary(unilong)
#multivariable models
for (i in 1:length(time)){
modm <- glm(rx ∼ dummy1+dummy2 + CD4count+ factor(Gender)+factor(Employ),
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family="binomial", data = longdata, subset = (longdata$yrlast >= time[i]))
longdata$xmeanm[longdata$stop yr == time[i]] <-
predict(modm,newdata=longdata[longdata$stop yr == time[i],],
type="response")
}
#second stage additive hazards model under 2SPS
unilongm<-aalen(Surv(start yr,stop yr, fdied==1) ∼ const(xmeanm)+const(CD4count)+
const(Gender)+const(Employ),robust=0, data=longdata)
summary(unilongm)
IV simulation for continuous exposure
#nsum is the sample size
#nsim is number of simulations per scenario
# x is an exposure
# d is a censor variable (1 if an event occurred, 0 if censoring occurred)
# u is unmeasured confounders
# ti is failure times
# beta0 is baseline hazard
#beta1 and betau are exposure and unmeasured confounder effect respectively
library(timereg)
nsum <- 1000
nsim<-1000
out.cross.iv<-numeric()
out.cross.iv u<-numeric()
out.cross u<-numeric()
#create study arms
102
arms <- sample(1:3,size=nsum,replace=TRUE,prob=c(0.333,0.333,0.333))
#create dummy variables
arm1<- ifelse(arms==1, 1, ifelse(arms==2,0,ifelse(arms==3,0,NA)))
arm2<- ifelse(arms==1, 0, ifelse(arms==2,1,ifelse(arms==3,0,NA)))
for(i in 1:nsim)
{
x<- rnorm(nsum, 0.04+0.74*arm1+0.34*arm2)
#change intercept when you change beta1 value and plot failure times
#to make sure they still follow exponential distribution
ti=rexp(nsum)/abs(lambda0+beta1*x)
d <- ifelse(ti<2,1,0)
ti <- pmin(ti,2)
data.cross<-data.frame(cbind(d,arm1,arm2,arms,ti,x))
lin <- lm(x ∼ arm1+arm2,data=data.cross)
data.cross$preduni <- predict(lin)
# second stage additive hazards model under 2SPS
model.cross.iv<-aalen(Surv(ti,d)∼ const(preduni),data=data.cross)
model.cross.iv.gamma=c(model.cross.iv$gamma)
out.cross.iv<-append(out.cross.iv,model.cross.iv.gamma)
u<-rnorm(nsum)
x u<- rnorm(nsum, 0.04+0.74*arm1+0.34*arm2+u)
#change intercept when you change beta1 value and plot failure times
#to make sure they still follow exponential distribution
ti u=rexp(nsum)/abs(lambda0+beta1*x u+beta0*u)
d u <- ifelse(ti u<2.0,1,0)
ti u <- pmin(ti u,2)
data.cross u<-data.frame(cbind(d u,arm1,arm2,arms,ti u,x u))
#second stage additive hazards model under 2SRI
model.cross u=aalen(Surv(ti u,d u)∼ const(x u)+const(u),data=data.cross u)
103
model.cross u.gamma=c(model.cross u$gamma)
out.cross u<-append(out.cross u,model.cross u.gamma)
# 2SPS approach adjusted for unmeasured confounding
lin u <- lm(x u∼ arms,data=data.cross u)
data.cross u$preduni u <- predict(lin u)
model.cross.iv u=aalen(Surv(ti u,d u)∼ const(preduni u),data=data.cross u)
summary(model.cross.iv u)
model.cross.gamma u=c(model.cross.iv u$gamma)
out.cross.iv u<-append(out.cross.iv u,model.cross.gamma u)
}
est.cross.iv<-c(rep(beta1,length(out.cross.iv)))
bias.cross.iv<-est.cross.iv-(out.cross.iv)
av.bias.cross.iv<-mean(bias.cross.iv)
est.cross u<-c(rep(beta1,length(out.cross u)))
bias.cross u<-est.cross u-(out.cross u)
av.bias.cross u<-mean(bias.cross u)
est.cross.iv u<-c(rep(beta1,length(out.cross.iv u)))
bias.cross.iv u<-est.cross.iv u-(out.cross.iv u)
av.bias.cross.iv u<-mean(bias.cross.iv u)
IV simulation for binary exposure
# variables including the study arms are explained as shown under the simulation
for linear exposure
for(i in 1:nsim)
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{
p =exp(0.8*arm1+0.5*arm2) / (1 + exp(0.8*arm1+0.5*arm2))
x =rbinom(nsum, size=1, prob=p)
#change intercept when you change beta1 value and plot failure times
#to make sure they still follow exponential distribution
ti=rexp(nsum)/abs(lambda0+beta1*x)
d <- ifelse(ti<2,1,0)
ti <- pmin(ti,2)
data.cross<-data.frame(cbind(d,arm1,arm2,arms,ti,x))
bin <- glm(a factor(arm1)+factor(arm2),binomial(link=’logit’),data=data.cross
data.cross$preduni<-predict(bin,type="response")
# second stage additive hazards model under 2SPS
model.cross.iv<-aalen(Surv(ti,d)∼ const(preduni),data=data.cross)
model.cross.iv.gamma=c(model.cross.iv$gamma)
out.cross.iv<-append(out.cross.iv,model.cross.iv.gamma)
u<-rnorm(nsum)
p u =exp(0.8*arm1+0.5*arm2+u) / (1 + exp(0.8*arm1+0.5*arm2+u))
x u =rbinom(nsum, size=1, prob=p u)
#change intercept when you change beta1 value and plot failure times
#to make sure they still follow exponential distribution
ti u=rexp(nsum)/abs(lambda0+beta1*x u+beta0*u)
d u <- ifelse(ti u<2.0,1,0)
ti u <- pmin(ti u,2)
data.cross u<-data.frame(cbind(d u,arm1,arm2,arms,ti u,x u))
#second stage additive hazards model under 2SRI
model.cross u=aalen(Surv(ti u,d u)∼ const(x u)+const(u),data=data.cross u)
model.cross u.gamma=c(model.cross u$gamma)
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out.cross u<-append(out.cross u,model.cross u.gamma)
# 2SPS approach adjusted for unmeasured confounding
bin u <- glm(a factor(arm1)+factor(arm2),binomial(link=’logit’),data=data.cross)
data.cross$preduni u<-predict(bin u,type="response")
model.cross.iv u=aalen(Surv(ti u,d u)∼ const(preduni u),data=data.cross u)
model.cross.gamma u=c(model.cross.iv u$gamma)
out.cross.iv u<-append(out.cross.iv u,model.cross.gamma u)
}
est.cross.iv<-c(rep(beta1,length(out.cross.iv)))
bias.cross.iv<-est.cross.iv-(out.cross.iv)
av.bias.cross.iv<-mean(bias.cross.iv)
est.cross u<-c(rep(beta1,length(out.cross u)))
bias.cross u<-est.cross u-(out.cross u)
av.bias.cross u<-mean(bias.cross u)
est.cross.iv u<-c(rep(beta1,length(out.cross.iv u)))
bias.cross.iv u<-est.cross.iv u-(out.cross.iv u)
av.bias.cross.iv u<-mean(bias.cross.iv u)
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